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BACKGROUND: There is debate whether body mass index is a good predictor of health outcomes because different tissues, 
namely skeletal muscle mass (SMM) and fat mass (FM), may be differentially associated with risk. We investigated the associa-
tion of appendicular SMM (aSMM) and FM with fatal and nonfatal cardiovascular disease (CVD) and all- cause mortality. We 
compared their prognostic value to that of body mass index.
METHODS AND RESULTS: We studied 356 590 UK Biobank participants aged 40 to 69 years with bioimpedance analysis data 
for whole- body FM and predicted limb muscle mass (to calculate aSMM). Associations between aSMM and FM with CVD 
and all- cause mortality were examined using multivariable Cox proportional hazards models. Over 3 749 501 person- years 
of follow- up, there were 27 784 CVD events and 15 844 all- cause deaths. In men, aSMM was positively associated with CVD 
incidence (hazard ratio [HR] per 1 SD 1.07; 95% CI, 1.06– 1.09) and there was a curvilinear association in women. There were 
stronger positive associations between FM and CVD with HRs per SD of 1.20 (95% CI, 1.19– 1.22) and 1.25 (95% CI, 1.23– 1.27) 
in men and women respectively. Within FM tertiles, the associations between aSMM and CVD risk largely persisted. There 
were J- shaped associations between aSMM and FM with all- cause mortality in both sexes. Body mass index was modestly 
better at discriminating CVD risk.
CONCLUSIONS: FM showed a strong positive association with CVD risk. The relationship of aSMM with CVD risk differed be-
tween sexes, and potential mechanisms need further investigation. Body fat and SMM bioimpedance measurements were not 
superior to body mass index in predicting population- level CVD incidence or all- cause mortality.
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The increasing prevalence of obesity is a significant public health concern because it is a known risk factor for several noncommunicable diseases,1– 5 
estimated to account for 56 million deaths globally in 
2017.6 Evidence from prospective cohort studies7– 10 
and meta- analyses of such studies2,11,12 has repeatedly 
shown a J- or U- shaped relationship between body 
mass index (BMI), cardiovascular disease (CVD), and 
all- cause mortality, even after efforts to account for 
confounding and reverse causality.12,13 A potential 
explanation for this is that BMI does not distinguish 
between fat mass (FM) and skeletal muscle mass 
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(SMM),12,13 yet their contribution to the pathogenesis of 
disease is likely to be different.
A systematic literature review of the associations 
between body composition and CVD or mortality 
(Data S1, Tables  S1 and S2) showed that the ma-
jority of studies found null or inverse associations 
with SMM, although a minority of studies reported 
positive or curvilinear associations. More studies 
have investigated the relationship of FM with these 
outcomes, with the majority of them reporting posi-
tive associations. Very few studies have investigated 
the combined impact of both types of tissues, yet 
weight change is associated with changes in both 
these body tissue compartments.
Dual energy X- ray absorptiometry (DEXA) or mag-
netic resonance imaging techniques are considered 
to be reference methods for the measurement of 
body composition because of their precision and 
reliability.14 However, these are often not feasible for 
large studies given they are expensive and not easily 
portable.15 Bioimpedance analysis (BIA) is a nonin-
vasive and practical method to assess FM and SMM 
in clinical practice and at scale in population- based 
studies.16– 18 The UK Biobank uses a bioimpedance 
analyzer previously validated against DEXA in a 
mixed population of children and adults, and body 
composition estimates were found to be more ac-
curate than those obtained from previous BIA esti-
mates.19 A recent validation study comparing BIA to 
DEXA in a subsample of the UK Biobank participants 
showed BIA to be a valid method for the assessment 
of appendicular skeletal muscle mass (aSMM) and 
FM.20
In this study we aimed to use BIA- derived aSMM 
and FM measurements to look at their associations 
with incident CVD and all- cause mortality in the UK 
Biobank population. Furthermore, to investigate the 
prognostic value of these BIA- derived measurements 
in comparison to more traditional measures such as 
BMI, grip strength, and waist circumference.
METHODS
Data Availability Statement
Researchers can apply to use the UK Biobank re-
source and access the data used. No additional data 
are available.
Study Design and Participants
The UK Biobank recruited 502 664 participants aged 
40 to 69  years between 2006 and 2010 (response 
rate 5.5%) via mailed invitations to the general public 
living within 25 miles of one of the 22 assessment 
centers in England, Scotland, and Wales.21,22 At the 
baseline assessment clinic, participants completed 
a touch- screen questionnaire and computer- assisted 
interview, had physical measurements taken, and 
biological samples collected.23,24 UK Biobank re-
ceived ethical approval from the North West Multi- 
centre Research Ethics Committee (REC reference: 
11/NW/03820). All participants gave written informed 
consent before enrolment in the study, which was 
CLINICAL PERSPECTIVE
What Is New?
• Reports of the relationship between muscle 
mass and cardiovascular disease (CVD) are 
inconsistent and have rarely been considered 
in the context of adiposity; analysis of body 
composition measured by bioimpedance in this 
large cohort of UK adults showed that fat mass 
showed strong positive associations with CVD 
events.
• Appendicular skeletal muscle mass had a cur-
vilinear association with CVD events in women 
and a positive association in men; the associa-
tions of appendicular skeletal muscle mass and 
fat mass with all- cause mortality followed a J- 
shape in both men and women.
• Measurements of body fat and skeletal muscle 
mass were not superior to body mass index in 
predicting CVD events or mortality.
What Are the Clinical Implications?
• Body mass index has been criticized as an inac-
curate measure of health risks, but at a popula-
tion level, more specific measurements of body 
composition, namely appendicular skeletal 
muscle mass and fat mass, were generally not 
more predictive of CVD events or mortality.
• Although body mass index may be the simplest 
measurement to assess health risk, which is im-
portant from a public health perspective, some 
of this risk may not be attributable solely to adi-
posity, particularly if the association observed 
with appendicular skeletal muscle mass in men 
is confirmed.
• Further research is needed to better under-
stand the biological mechanisms and impact 
of different body tissue compartment on health 
outcomes.
Nonstandard Abbreviations and Acronyms
aSMM appendicular skeletal muscle mass
BIA bioimpedance analysis
FM fat mass
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conducted in accordance with the principles of the 
Declaration of Helsinki.
Participants were excluded from analyses if they 
had prior CVD (defined later) or diseases that may af-
fect body composition including fractures in the past 
year, respiratory diseases, musculoskeletal conditions, 
and some infectious diseases (n=116 679; Figure S1).25 
Participants were also excluded if they had missing 
data for the exposures (n=6751) or were not of a White 
race (n=22  644), because BIA estimates are derived 
from algorithms in White populations, which represent 
≈95% of the UK Biobank sample.26– 28
Measurement of Exposures
Measures of body weight and body composition 
(muscle mass and fat mass) were derived from BIA in 
bare- footed participants wearing light clothing using 
a Tanita BC418MA single frequency segmental body- 
composition analyzer (Tanita, Tokyo, Japan) at the 
baseline assessment center visit. The aSMM (kg) was 
calculated as the sum of the predicted muscle mass 
from the 4 limbs. Whole body FM (kg) was also ob-
tained from BIA. Standing height was measured using 
a Seca 202 scale (Seca, Hamburg, Germany). BMI 
was calculated by dividing weight (kg) by the squared 
height in meters.
Waist circumference (cm) was measured at the um-
bilicus using a tape measure. The mean grip strength 
(kg) of the left and right hands was taken once using a 
Jamar J00105 hydraulic hand dynamometer.
Ascertainment of Outcomes
Participants were followed via linkage to National 
Health Service hospital in- patient data from hospital 
episode statistics in England, the Scottish Morbidity 
Records, and the Patient Episode Database for Wales. 
Patients were identified if they died of any cause or 
developed incident CVD, defined using International 
Statistical Classification of Diseases, Tenth Revision 
(ICD- 10) categories: coronary heart disease (I21– I24, 
125.6, I42, I43, K49, K50, K75, K40– K46), congestive 
heart failure or cardiomyopathy (I50, I50.1, 150.9, I11.0, 
I13.0, I13.2), and total stroke (I60– I64).29 Follow- up was 
available until June 30, 2020, October 31, 2016, and 
February 29, 2016 for England, Scotland, and Wales 
respectively; and until July 31, 2020 for all- cause mor-
tality for all regions.
Statistical Analysis
Association of Skeletal Muscle Mass and Fat 
Mass With CVD and Mortality
First, age- adjusted partial correlation coefficients be-
tween aSMM, FM, and height were calculated to ex-
amine the relationships between the body composition 
measurements and overall body size. As aSMM is 
highly correlated with FM and height,30 aSMM was re-
gressed on height and FM and the residuals from this 
model were divided into sex- specific quintiles for the 
main analysis.
Multivariable Cox regression analyses with age as 
the underlying timescale were used to estimate haz-
ard ratios (HRs) and 95% CIs for the associations of 
sex- specific fifths of aSMM and fifths of FM as well as 
per 1 SD with incident CVD and all- cause mortality. 
All analyses were sequentially adjusted for height and 
height2 (continuous), Townsend index of deprivation 
(quintiles), level of education (none, vocational quali-
fications, any degree, higher degree, other), smoking 
(never, previous, current), alcohol intake (none, <1 unit/
week, 1– 14 units/week, 14+ units/week), physical ac-
tivity derived from metabolic equivalent of task scores 
(low, moderate, high),31 and dietary factors (oily fish 
intake, saturated fat intake, fruit and vegetable intake 
[none, low, medium, high intake]), prior medical history 
(diabetes mellitus, cancer history >5  years ago, and 
menopausal status in women [binary for each]). We 
created a category for missing values for each of these 
covariates. Additionally, FM and aSMM were mutually 
adjusted for each other to assess the independent ef-
fects of each type of tissue. See Table S3 for the details 
on the derivation of these covariates.
The HRs and 95% CIs were computed using 
group- specific variances32; these reflect the uncer-
tainty in the estimate of risk in each group (including 
the reference group), thereby allowing comparisons 
between any 2 quintiles independently of the refer-
ence group. Restricted cubic splines with 5 knots 
were also computed to visually explore nonlinear 
associations for continuous exposures, and depar-
tures from linearity were tested via the likelihood ratio 
statistic test used to evaluate if models with linear 
or categorical exposures were a better fit.33 Five 
knots were specified to be consistent with the quin-
tile analysis but also to provide enough flexibility to 
the model while also not being too many knots so 
that the model is oversensitive to the smallest fluctu-
ations.34,35 To correct for the measurement error that 
can arise from using a single baseline measurement 
to estimate long- term exposure status (ie, regression 
dilution bias),36 mean values of BIA measurements 
at resurvey (2012– 2013) from 15  694 participants 
were used in 2 ways. First, the HR (95% CI) in the 
baseline- defined groups of aSMM and FM were 
plotted against the mean resurvey values in those 
baseline- defined groups (termed the “usual” value). 
Second, where there was evidence of a log- linear re-
lationship, regression dilution ratios were calculated 
using the MacMahon- Peto method.37 The log HRs 
(and theirSEs) per 1 SD of baseline aSMM and FM 
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ratio to obtain HRs (and associated 95% CI) per 1 SD 
of usual aSMM and FM.37
Sensitivity analyses were conducted to assess 
potential residual confounding or reverse causality 
so additional exclusions were made for events that 
occurred during the first 2 years of follow- up to re-
duce the impact of reverse causality, for outliers, or 
for participants with BMI over 35 kg/m2 for whom BIA 
measurements may be less accurate. Additional ad-
justments were made for BMI (instead of FM in the 
SMM model and instead of SMM in the FM model) as 
well as for hypertension (diagnosed by doctor, taking 
medication, or blood pressure measurement), and 
blood cholesterol (defined as taking medication, plus 
levels of non- high- density lipoprotein cholesterol and 
triglycerides) to investigate if these are potential me-
diators of the associations. Finally, Cox regression 
models were conducted with BMI as the exposure 
as a “positive control” to confirm that the specified 
models would produce the same association that 
has been documented previously.9
Associations of aSMM Within Tertiles of FM
To better assess the independent association of 
aSMM with the risk of disease, irrespective of its 
strong correlation with FM, we examined the sex- 
specific associations of aSMM within subgroups of 
FM tertiles (subsequently referred to as "body compo-
sition groups," because we looked at low/moderate/
high groups [tertiles] of aSMM within groups of FM). 
Multivariable Cox models adjusting for all covariates 
listed previously were used to assess the associations 
with CVD and all- cause mortality using "moderate" 
aSMM as the reference category within each tertile 
of FM.
Prognostic Comparison of aSMM, FM, and 
Body Composition Groups With BMI, Waist 
Circumference, and Grip Strength
The relative importance of the various measures in 
prediction of CVD or mortality was assessed in sev-
eral ways. First, where a linear association was pre-
sent, the HRs associated with 1 usual SD change were 
compared for each measure. In order to assess the 
discriminatory ability of each measure with CVD and 
mortality Harrell’s C- statistic from the area under the 
receiver operating curve was computed.38 Third, the 
Wald test χ2 statistic was used to compare a model 
with just confounders to a model with confounders 
plus the exposure of interest to explore how much of 
the variation in risk is explained by each exposure of 
interest, given confounders.39
All analyses were conducted using Stata 15.0 
for analyses and R 3.5.2 for graphs. Analyses used 




After exclusions, the final sample included 356  590 
adults who were followed for a median of 10.5 years 
during which there were 27 784 CVD events and 15 844 
deaths due to all causes. The mean age at recruitment 
was 56 (SD 8) years. Men had a higher aSMM (me-
dian 27.2 kg in men; and 18.3 kg in women), although 
the difference between the sexes was smaller for FM 
(median 21.8 kg in men, 26.3 kg in women; Table 1, 
Tables  S4 and S5). There were strong partial corre-
lations between aSMM and FM (men r=0.71, women 
r=0.78) and aSMM and height (men r=0.52, women 
r=0.44) but not between FM and height (r=men 0.14, 
women 0.15; Table S6).
Participants in the highest quintiles of aSMM and 
FM had similar diets (ie, high saturated fat intake, 
low oily fish intake, but similar fruit and vegetable 
intakes), and a higher percentage of participants 
had low physical activity and a higher prevalence of 
type 2 diabetes mellitus and hypertension. A higher 
percentage of participants in the highest FM quin-
tile were taking medication for cholesterol but there 
were no differences across aSMM quintiles (Table 1, 
Tables S4 and S5).
Associations of Skeletal Muscle Mass and 
Fat Mass With Health Outcomes
There was a potential curvilinear association be-
tween aSMM and CVD in women (likelihood ratio test 
statistic of nonlinearity [df=4], P<0.001) with the nadir 
approximately at the median; this curvilinear shape 
was even more pronounced in the cubic spline analy-
sis (Figure 1, Figure S2, Table S7). There was a posi-
tive linear association in men with an HR per 1 usual 
SD of 1.07 (95% CI, 1.06– 1.09). FM showed much 
stronger positive log- linear associations with the risk 
of CVD with HRs per 1 usual SD of 1.20 (95% CI, 
1.19– 1.22) in men and 1.25 (95% CI, 1.23– 1.27) in 
women (Figure 1, Figure S2, Table S7). These asso-
ciations were similar across CVD subtypes (nonfatal, 
fatal, coronary heart disease, congestive heart fail-
ure, and stroke) for both aSMM and FM (Figure S3). 
The associations of aSMM and FM with all- cause 
mortality generally followed a J- shape in both men 
and women, although the association with FM was 
more clear (Figure 2, Figure S2, Table S8).
These findings remained robust after sensitiv-
ity analyses (Tables  S9 and S10). Exclusion of the 
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Table 1. Baseline Characteristics of the Study Population According to Appendicular Skeletal Muscle Mass and Fat Mass 
Quintiles in 356 590 UK Biobank Participants
Men Appendicular Skeletal Muscle Mass 














Age at recruitment, y, mean 
(SD)
61.0 (6.4) 56.0 (7.8) 51.7 (7.8) 54.9 (8.3) 56.5 (8.1) 56.9 (7.8) 56.2 (8.1)
aSMM, kg, mean (SD) 24.6 (2.9) 26.9 (2.9) 30.5 (3.6) 24.6 (2.7) 26.7 (2.7) 31.0 (3.6) 27.2 (3.7)
FM, kg, mean (SD) 22.4 (7.1) 21.4 (7.4) 22.2 (9.2) 12.4 (2.4) 21.0 (1.0) 33.6 (6.2) 21.8 (7.8)
BMI, kg/m2, mean (SD) 26.0 (3.5) 27.4 (3.6) 29.7 (4.4) 23.3 (1.8) 27.1 (1.6) 33.1 (3.5) 27.6 (4.0)
Higher education, n (%) 12 740 (39.7%) 13 140 (40.9%) 12 645 
(39.3%)
13 909 (43.1%) 12 987 (40.6%) 11 735 (36.7%) 64 706 (40.2%)
Current smokers, n (%) 3714 (11.6%) 3573 (11.1%) 3724 (11.6%) 4366 (13.5%) 3368 (10.5%) 3286 (10.3%) 18 005 (11.2%)
Low fruit and vegetable 
intake, n (%)
14 779 (46.0%) 13 977 (43.5%) 13 367 (41.6%) 13 624 (42.2%) 14 191 (44.3%) 14 349 (44.8%) 70 241 (43.7%)
High saturated fat intake, 
n (%)
11 706 (36.4%) 11 647 (36.2%) 11 778 (36.6%) 10 457 (32.4%) 11 699 (36.6%) 12 933 (40.4%) 58 554 (36.4%)
Low oily fish intake, n (%) 10 919 (34.0%) 11 342 (35.3%) 11 988 (37.3%) 11 197 (34.7%) 11 518 (36.0%) 11 661 (36.4%) 57 348 (35.7%)
Heavy drinkers, n (%) 19 948 (62.1%) 19 841 (61.7%) 18 666 (58.1%) 17 562 (54.4%) 20 297 (63.4%) 19 695 (61.5%) 97 948 (60.9%)
Low physical activity, n (%) 7247 (22.6%) 6300 (19.6%) 5518 (17.2%) 4580 (14.2%) 6030 (18.8%) 8757 (27.4%) 31 636 (19.7%)
Hypertension, n (%) 20 146 (62.7%) 18 102 (56.3%) 17 370 (54.0%) 12 683 (39.3%) 18 523 (57.9%) 23 544 (73.5%) 91 858 (57.1%)
Type 2 diabetes mellitus, n (%) 1300 (4.1%) 1156 (3.6%) 1408 (4.4%) 388 (1.2%) 906 (2.8%) 2883 (9.0%) 6305 (3.9%)
Cancer history (>5 y ago), n (%) 1176 (3.7%) 816 (2.5%) 652 (2.0%) 780 (2.4%) 856 (2.7%) 889 (2.8%) 4233 (2.6%)
Cholesterol medication, n (%) 6204 (19.5%) 4646 (14.6%) 3842 (12.0%) 2175 (6.8%) 4664 (14.7%) 7440 (23.4%) 24 008 (15.0%)
Women Appendicular Skeletal Muscle 














Age at recruitment, y, mean 
(SD)
58.9 (7.0) 55.8 (7.9) 53.2 (8.1) 54.1 (8.1) 56.6 (7.9) 56.4 (7.8) 55.9 (8.0)
aSMM, kg, mean (SD) 17.0 (1.7) 18.0 (1.8) 20.3 (2.5) 16.6 (1.5) 17.9 (1.4) 21.1 (2.3) 18.3 (2.3)
FM, kg, mean (SD) 27.7 (8.5) 25.5 (8.8) 27.0 (11.9) 15.2 (2.6) 24.9 (1.3) 41.1 (7.4) 26.3 (9.6)
BMI, mean (SD) 25.9 (4.2) 26.3 (4.4) 28.5 (6.0) 21.6 (1.7) 25.9 (1.7) 33.9 (4.3) 26.7 (4.9)
Higher education, n (%) 14 330 (36.6%) 16 033 (40.9%) 17 056 (43.6%) 18 112 (45.5%) 15 834 (39.8%) 14 209 (36.4%) 79 178 (40.4%)
Current smokers, n (%) 3039 (7.8%) 3231 (8.2%) 3377 (8.6%) 3792 (9.5%) 3151 (7.9%) 2898 (7.4%) 16 069 (8.2%)
Low fruit and vegetable intake, 
n (%)
12 608 (32.2%) 11 874 (30.3%) 10 910 (27.9%) 12 125 (30.5%) 11 756 (29.6%) 12 234 (31.3%) 59 246 (30.3%)
High saturated fat intake, n (%) 11 699 (29.9%) 11 252 (28.7%) 11 212 (28.6%) 10 415 (26.2%) 11 615 (29.2%) 12 439 (31.9%) 57 055 (29.1%)
Low oily fish intake, n (%) 12 200 (31.2%) 12 619 (32.2%) 13 137 (33.6%) 12 971 (32.6%) 12 669 (31.8%) 13 082 (33.5%) 63 668 (32.5%)
Heavy drinkers, n (%) 12 955 (33.1%) 13 025 (33.2%) 12 318 (31.5%) 13 562 (34.1%) 13 525 (34.0%) 10 970 (28.1%) 64 272 (32.8%)
Low physical activity, n (%) 10 117 (25.8%) 8431 (21.5%) 7837 (20.0%) 6398 (16.1%) 8288 (20.8%) 12 160 (31.1%) 43 345 (22.1%)
Hypertension, n (%) 19 371 (49.5%) 16 440 (42.0%) 16 330 (41.7%) 11 345 (28.5%) 17 091 (43.0%) 23 766 (60.9%) 85 687 (43.8%)
Type 2 diabetes mellitus, n (%) 635 (1.6%) 669 (1.7%) 1250 (3.2%) 239 (0.6%) 524 (1.3%) 2046 (5.3%) 4032 (2.1%)
Cancer history (>5 y ago), n (%) 2540 (6.5%) 2010 (5.1%) 1845 (4.7%) 1912 (4.8%) 2278 (5.7%) 2170 (5.6%) 10 626 (5.4%)
Cholesterol medication, n (%) 4294 (11.0%) 3163 (8.1%) 3080 (7.9%) 1536 (3.9%) 3349 (8.5%) 5721 (14.8%) 17 157 (8.8%)
Postmenopausal, n (%) 28 352 (72.4%) 23 352 (59.6%) 17 594 (44.9%) 21 266 (53.5%) 24 686 (62.1%) 22 973 (58.8%) 116 065 
(59.3%)
χ2 test for trend was performed with P<0.05 for all characteristics across the aSMM and FM quintiles. All characteristics were determined at the baseline 
assessment clinic through touch- screen questionnaires, interviews, and/or physical measurements. Higher education: college or university degree or 
professional qualifications. Low physical activity: <600 metabolic equivalent (MET)- minutes per week.31 Heavy alcohol drinker: >14 units of alcohol a week).40 
Hypertension: systolic blood pressure >140 mm Hg, diastolic blood pressure >90 mm Hg, was diagnosed by a doctor or were taking medication to lower blood 
pressure. Diabetes mellitus and cholesterol: taking medication for these conditions or diagnosed by a doctor. Cancer history: diagnosed with cancer >5 years 
ago (those with more recent cancer had been excluded). Low fruit and vegetable intake: the lowest consumption tertile (<21 portions per week). High saturated 
fat: the highest saturated fat tertile, based on portions per week of beef, lamb, pork, and whether they consumed animal- or plant- based spreads. Low oily fish: 
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causality, outliers, or participants with BMI >35 kg/m2 
did not affect the associations.
Adjustment for hypertension and high blood choles-
terol as mediators did not affect associations of aSMM 
with CVD or all- cause mortality. These mediators ex-
plained ≈30% to 40% of the χ2 statistic in models of FM 
and CVD, although the association between FM and 
all- cause mortality was affected less (Tables S11 and 
Figure 1. Adjusted hazard ratios (HRs) of incident cardiovascular disease associated with 
appendicular skeletal muscle mass (aSMM) and fat mass (FM).
A, HRs of incident CVD associated with aSMM in men, 1 SD=5.66 kg. B, HRs of incident CVD associated 
with aSMM in women, 1 SD=1.45 kg. C, HRs of incident CVD associated with FM in men, 1 SD=6.75 kg. D, 
HRs of incident CVD associated with FM in women, 1 SD=8.28 kg. For all panels, likelihood ratio tests were 
used to estimate nonlinearity (aSMM in men, P=0.04; aSMM in women, P<0.001; FM in men, P=0.09; FM in 
women, P=0.09). Adjusted HRs and CIs obtained using the floated absolute risk method of Cox proportional 
hazards regression, number of cases shown above each estimate and HRs shown below. Adjusted for age 
(underlying timescale variable), height (as a continuous variable in FM and included by regression out of 
variation due to height for aSMM), Townsend index of deprivation, education, smoking status, alcohol 
intake, physical activity, oily fish intake, fruit and vegetable intake, saturated fat intake, diabetes mellitus, 
cancer history, menopause (women), and mutually adjusted for FM (in the aSMM models) and aSMM (in the 
FM models). HRs are plotted at the mean of the resurvey values for the baseline- defined quintiles (“usual” 
values) to correct for measurement error. HRs per 1 SD given where there was no evidence of departure 
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Figure 2. Adjusted hazard ratios (HRs) of all- cause mortality associated with appendicular 
skeletal muscle mass (ASMM) and fat mass (FM).
A, HRs of all- cause mortality associated with aSMM in men, 1 SD=5.66 kg. B, HRs of all- cause mortality 
associated with aSMM in women, 1 SD=1.45 kg. C, HRs of all- cause mortality associated with FM in 
men, 1 SD=6.75  kg. D, HRs of all- cause mortality associated with FM in women, 1 SD=8.28  kg. For 
all panels, likelihood ratio tests were used to estimate nonlinearity P values (aSMM in men, P=0.002; 
aSMM in women, P=0.008; FM in men, P<0.001; FM in women, P<0.001). Adjusted HRs and CIs obtained 
using the floated absolute risk method of Cox proportional hazards regression, number of cases shown 
above each estimate and HRs shown below. Adjusted for age (underlying timescale variable), height (as a 
continuous variable in FM and included by regression out of variation due to height for aSMM), Townsend 
index of deprivation, education, smoking status, alcohol intake, physical activity, oily fish intake, fruit 
and vegetable intake, saturated fat intake, diabetes mellitus, cancer history, menopause (women), and 
mutually adjusted for FM (in the aSMM models) and aSMM (in the FM models). HRs are plotted at the 
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S12). However, adjustment for BMI (instead of SMM 
or FM in their respective models) removed the posi-
tive association between aSMM and CVD in men but 
did not change the association observed in women. 
Associations between FM and CVD and all- cause 
mortality were largely attenuated after adjustment for 
BMI, with large % of the χ2 statistic explained in both 
men and women.
Analyses of body composition groups (aSMM ter-
tiles within each FM tertile) showed positive linear as-
sociations between aSMM and incident CVD risk in 
men in all FM tertiles, whereas women still had cur-
vilinear associations with incident CVD except those 
in the highest FM tertile (Figure 3). The associations 
of aSMM with all- cause mortality within FM tertiles 
were broadly similar between men and women and 
to those observed in the main analysis, except for 
women in the middle tertile of FM, which showed a 
curvilinear association between aSMM and all- cause 
mortality.
Comparing the Prognostic Value of Body 
Composition Measures
For CVD risk, waist circumference and FM showed 
the strongest associations whereas aSMM and grip 
strength showed the weakest associations in both men 
and women. For all- cause mortality, waist circumfer-
ence and grip strength showed the strongest associa-
tions, whereas aSMM remained the weakest (Figure 4, 
Table  2). However, the discriminatory performance 
(Harrell’s C- statistics) for total CVD was slightly higher for 
BMI compared with all the other metrics in men (C=0.63; 
95% CI, 0.63– 0.64) and for BMI and waist circumfer-
ence in women (C=0.45; 95% CI, 0.45– 0.45). Similarly, 
for all- cause mortality, the discriminatory performance 
was highest for BMI (C=0.62; 95% CI, 0.62– 0.63) and 
waist circumference (C=0.61; 95% CI, 0.61– 0.62) in 
men, whereas in women it was FM (C=0.63; 95% CI, 
0.62– 0.63) and aSMM (C=0.63; 95% CI, 0.62– 0.63). 
The χ2 statistic was marginally higher in the BMI and 
waist circumference model in men and in the BMI and 
the combined aSMM/FM groups in women.
DISCUSSION
In this prospective study of 356 590 UK adults, FM 
had a strong positive log- linear association with the 
risk of CVD in both sexes. There was also a posi-
tive log- linear association with aSMM for men and a 
curvilinear association for women. The associations 
of aSMM and FM with all- cause mortality followed 
a J- shape in both men and women. Analysis of the 
association of aSMM within tertiles of FM supported 
these associations with CVD and all- cause mortality. 
The discriminatory ability of BMI was similar to, or 
better than, more specific measures of body com-
position (aSMM and FM), waist circumference, or 
grip strength in relation to CVD events or all- cause 
mortality.
Few previous studies have specifically examined 
the association between distinct body compart-
ments with either incident CVD or mortality. In line 
with previous studies we consistently observed a 
positive association between FM and CVD. This is 
consistent with previous analyses from UK Biobank 
that found significant associations between body fat 
percentage, waist circumference, and waist- to- hip 
ratio on CVD outcomes9 as well as meta- analyses 
of prospective cohort studies assessing various adi-
posity measures.3,41
The role of aSMM has been investigated in fewer 
studies, most of which used older populations with 
small sample sizes or a proxy for aSMM such as 
fat- free mass.42– 46 Our rationale for using aSMM as 
opposed to whole body muscle or fat- free mass is 
because this tissue is more likely to be modifiable by 
lifestyle factors such as physical activity than other 
components of fat- free mass and it is less likely to be 
confounded by FM given that higher abdominal FM is 
often accompanied by greater muscle in the trunk re-
gion.30 However, aSMM is a large contributor to whole 
body muscle and it is likely that participants would be 
classified in the same quintile regardless of the mea-
sure used. Although some studies have shown an in-
verse association between aSMM and CVD risk, our 
finding of a positive log- linear association among men 
Figure 3. Adjusted hazard ratios (HRs) of cardiovascular disease and all- cause mortality associated with appendicular 
skeletal muscle mass (aSMM) when participants are stratified into fat mass (FM) tertiles.
A, HRs of cardiovascular disease (CVD) associated with aSMM in low fat men. B, HRs of CVD associated with aSMM in moderate fat 
men. C, HRs of CVD associated with aSMM in high fat men. D, HRs of CVD associated with aSMM in low fat women. E, HRs of CVD 
associated with aSMM in moderate fat women. F, HRs of CVD associated with aSMM in high fat women. G, HRs of all- cause mortality 
associated with aSMM in low fat men. H, HRs of all- cause mortality associated with aSMM in moderate fat men. I, HRs of all- cause 
mortality associated with aSMM in high fat men. J, HRs of all- cause mortality associated with aSMM in low fat women. K, HRs of all- 
cause mortality associated with aSMM in moderate fat women. L, HRs of all- cause mortality associated with aSMM in high fat women. 
For all panels, adjusted hazard ratios (HR) and CIs obtained using Cox proportional hazards regression, number of cases shown above 
each estimate and HRs shown below. Adjusted for age (underlying timescale variable), height (included by regression out of variation 
due to height), Townsend index of deprivation, education, smoking status, alcohol intake, physical activity, oily fish intake, fruit and 
vegetable intake, saturated fat intake, diabetes mellitus, cancer history, menopause (women), and mutually adjusted for FM (in the 
aSMM models) and aSMM (in the FM models). HRs are plotted at the mean of the resurvey values for the baseline- defined quintiles 
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has been observed previously. The Aerobics Center 
Longitudinal Study found a similar pattern with fat- 
free mass index measured by skinfold thicknesses 
as well as hydrostatic weighing (for which aSMM is 
the largest contributor) and had a comparably aged, 
predominantly male study population.47 A plausible 
physiological mechanism linking higher aSMM with 
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volume, which increases cardiac output and in-
creases systolic blood pressure and the risk of heart 
failure, a phenomenon previously described mainly 
among people with obesity.48– 50 A recent literature 
review has provided a more counterintuitive view of 
the role of lean mass on metabolic health, propos-
ing the possibility of publication bias, especially if 
unexpected results were found.51 Our analysis within 
tertiles of FM confirmed the increased risk of CVD 
with aSMM even among men with lower FM levels, 
reducing the possibility of residual confounding by 
FM although this cannot be completely ruled out. Our 
exploratory mediation analyses showed that the as-
sociation between aSMM and CVD was no longer 
significant in men after adjusting for BMI. This implies 
that if aSMM increases, FM plus all the other body 
compartments have to decrease in order to hold 
BMI constant, such that changes in body composi-
tion that increase skeletal muscle while lowering total 
body fat, as expected with physical training, may not 
be associated with increased CVD risk. Furthermore, 
the large changes observed in the χ2 statistic after 
adjustment for BMI in the aSMM model suggest a 
large part of the association may be explained by 
confounding by BMI, especially among men.
Nevertheless, it is unusual to find a CVD risk fac-
tor with such different associations between sexes.52 
A potential explanation for this disparity could be be-
cause of differences in lifestyle factors between men 
and women classified as high aSMM within each FM 
tertile. For example, compared with women, a higher 
percentage of men in the same aSMM and FM tertile, 
reported poorer diets (low fruit and vegetable intake, 
high saturated fat intake), heavy drinking (over 14 units/
week, National Health Service guidelines), or presented 
a higher prevalence of hypertension and cholesterol 
medication. Our findings are largely consistent with 
those reported from a recent study of 38 000 middle- 
aged men that demonstrated a U- shaped association 
between predicted lean mass and CVD death and 
mortality; however, these participants may have been 
healthier because they recruited health professionals 
rather than the general population.53 Although we ad-
justed for several potential lifestyle confounders our 
study may still have residual confounding in relation to 
lifestyle factors.
Figure 4. Independent effects of body mass index (BMI), fat mass (FM), waist circumference, appendicular skeletal muscle 
mass (aSMM), and grip strength on cardiovascular disease (CVD) subtypes and all- cause mortality. Adjusted hazard ratios 
(HRs) per SD change.
A, The independent effects of BMI, FM, waist circumference, aSMM and grip strength on CVD subtypes and all- cause mortality in 
men. B, The independent effects of BMI, FM, waist circumference, aSMM, and grip strength on CVD subtypes and all- cause mortality 
in women. Range excludes outliers. Adjusted hazard ratios (HR) and CIs obtained using Cox proportional hazard regression. Adjusted 
for age (underlying timescale variable), height (as a continuous variable in all models except aSMM where it was included by regression 
out of variation due to height for aSMM), Townsend index of deprivation, education, smoking status, alcohol intake, physical activity, 
oily fish intake, fruit and vegetable intake, saturated fat intake, diabetes mellitus, cancer history, menopause (women), and mutually 
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Clinical and Public Health Implications
BMI has been criticized as an inaccurate measure of 
health risks,54,55 but at a population level, more spe-
cific measurements of body composition, namely 
aSMM and FM, were generally not more predictive of 
CVD events or mortality; an observation that also been 
reported elsewhere.47,56,57 The moderately improved 
prognostic value of BMI may reflect the combined ef-
fects of height, FM, and SMM that are each individually 
associated with CVD risk.58 In addition, BMI has less 
measurement error than other measures that could 
contribute to its marginally stronger prognostic abil-
ity.50 Waist circumference and other measures of cen-
tral adiposity have been reported to better discriminate 
CVD risk in some studies,59 although not superior to 
BMI in others60 as happened in our study. However, 
waist circumference is particularly liable to observer 
error,50 whereas measures of central adiposity do not 
indicate whole- body adiposity, nor is there an equiva-
lent measure for fat- free mass. Grip strength is often 
used as a functional indicator of SMM; however, it 
includes a volitional component and the European 
Working Group of Sarcopenia in Older People rec-
ommends measuring the amount of SMM to assess 
risk.61 However, the commonly used measure of the 
mid- upper arm circumference is vulnerable to overes-
timation because it cannot distinguish between muscle 
fibers and intramuscular fat deposits.61
However, although BMI may be the simplest mea-
surement to assess health risk, which is important 
from a public health perspective, some of this risk may 
not be attributable solely to adiposity, particularly if the 
association observed with aSMM in men is confirmed, 
although further research is needed to better under-
stand the biological mechanisms and impact of differ-
ent body tissue compartment on health outcomes. It 
could therefore be beneficial to reframe BMI as a com-
posite measure of risk.47,58 In addition, at the individual 
level, additional measurements of CVD risk factors (eg, 
blood lipids, blood pressure) in addition to BMI or body 
composition are needed to classify individuals at risk 
and propose adequate treatments.
Strengths and Weaknesses of the Study
The strengths of this study include its large sample 
size, which reduces the risk of chance findings owing 
to random error, and the detailed measurements of 
the exposures, potential confounders, and outcomes 
from the hospital episode statistics follow- up. Some 
participants had repeated measurements taken at 
resurvey, which allowed for the correction for random 
measurement error and consequent regression dilu-
tion bias.36
Although BIA has many practical strengths in re-
search and clinical settings, it is not as accurate as 
other methods that use physical properties of the 
Table 2. The Discrimination Ability of Each Body Composition Measure for the Prediction of Cardiovascular Events and 









HR Per SD 
(95% CI)
Harrell’s C- Statistic 
(95% CI)
HR Per SD 
(95% CI)
Harrell’s C- Statistic 
(95% CI)
Cardiovascular disease
BMI 1.15 (1.14– 1.16) 0.63 (0.63– 0.64) 597 1.18 (1.16– 1.19) 0.45 (0.45– 0.45) 462
FM 1.20 (1.19– 1.22) 0.56 (0.55– 0.56) 445 1.25 (1.23– 1.27) 0.59 (0.58– 0.59) 374
Waist circumference 1.23 (1.21– 1.25) 0.61 (0.61– 0.62) 492 1.31 (1.28– 1.33) 0.45 (0.44– 0.45) 464
aSMM 1.07 (1.06– 1.09) 0.54 (0.54– 0.54) 73 1.00 (0.98– 1.02) 0.57 (0.56– 0.57) 0
Decreasing grip strength 1.09 (1.07– 1.12) 0.55 (0.54– 0.55) 42 1.11 (1.08– 1.14) 0.44 (0.43– 0.44) 51
Body composition groups … 0.56 (0.55– 0.56) 504 … 0.45 (0.44– 0.45) 400
All- cause mortality
BMI 1.08 (1.06– 1.09) 0.62 (0.62– 0.63) 79 1.06 (1.05– 1.08) 0.61 (0.61– 0.62) 40
FM 1.08 (1.06– 1.1) 0.60 (0.59– 0.60) 39 1.05 (1.02– 1.08) 0.63 (0.62– 0.63) 11
Waist circumference 1.13 (1.1– 1.15) 0.61 (0.61– 0.62) 84 1.09 (1.06– 1.12) 0.61 (0.6– 0.62) 29
aSMM 1.04 (1.01– 1.06) 0.60 (0.59– 0.60) 9 0.98 (0.92– 1.04) 0.63 (0.62– 0.63) 0
Decreasing grip strength 1.17 (1.13– 1.2) 0.60 (0.60– 0.61) 70 1.08 (1.04– 1.11) 0.61 (0.60– 0.61) 18
Body composition groups … 0.61 (0.61– 0.62) 83 … 0.61 (0.61– 0.62) 41
Harrell’s C- statistic and hazard ratios (HR) per SD change calculated from the fully- adjusted model, which adjusted for: age (underlying timescale variable), 
height, Townsend index of deprivation, education, smoking status, alcohol intake, physical activity, oily fish intake, fruit and vegetable intake, saturated fat 
intake, diabetes mellitus, cancer history, menopause (women), and mutually adjusted for FM (in the aSMM models) and aSMM (in the FM models). HRs are 
corrected for regression dilution bias using the MacMahon- Peto method. One SD of aSMM is 3.34 kg (men), 1.95 kg (women) and FM is 6.79 kg (men), 8.29 kg 
(women). The model for aSMM in men is for increasing aSMM; in women is for decreasing aSMM. Wald test χ2
1
 statistic was used to compare a model with just 
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body to measure composition, such as densitometry 
or DEXA or imaging methods such magnetic reso-
nance imaging scans, and is vulnerable to estimation 
errors, especially at the extreme ranges of BMI or in 
people with conditions that affect water retention.17,62 
However, validation studies against DEXA show that 
it performs well in healthy individuals with a stable 
electrolyte and water balance.20 Because algorithms 
to estimate body composition by BIA vary, it may be 
that our results can be replicated only using a Tanita 
BC- 418 MA segmental body composition analyzer. 
However, studies comparing different analyzers from 
this manufacturer or others have reported only small 
differences in % body fat (eg, equivalent to 0.7  kg 
of difference in FM),63 suggesting that a participant 
would likely fall into the same quintile regardless of 
the method used.
Despite the large sample of participants stud-
ied here, one of the main limitations is that the UK 
Biobank presents a low response rate for the United 
Kingdom (5.5%); however, the associations in this 
study should still be valid and not affected by se-
lection bias.64 The participants were predominantly 
people of White race, which limits the generaliz-
ability of our findings. Despite the performance of 
BMI in this high- income population of UK Biobank, 
there is emerging evidence that suggests that BMI 
is not an informative measure of risk for mortality 
in lean populations from low- and middle- income 
countries. For example, research from a large co-
hort study of 0.5 million adults in India found little 
association between BMI and cardiac mortality.65 It 
may be that BMI is a better indicator of risk in popu-
lations where fat mass is the dominant type of body 
tissue, supported in the current study by the largely 
equivalent associations of BMI and fat mass with 
the risk of CVD. Research has also suggested that 
the distribution of fat mass within equivalent lev-
els of BMI may have distinct associations with the 
risk of cardiometabolic diseases in different ethnic 
groups.66 Thus, although BMI may be the most ef-
fective tool for risk assessment within high- income 
populations further work is needed to compare its 
prognostic ability with more detailed measures of 
body composition in diverse populations. Finally, as 
this is an observational study we cannot eliminate 
the possibility that residual confounding affected 
our results.
CONCLUSIONS
FM showed a strong positive association with CVD 
risk whereas SMM showed a positive log- linear as-
sociation with CVD risk in men but curvilinear in 
women. Although BMI has been criticized as an 
inaccurate measure of risk, more specific measure-
ments of body composition did not demonstrate im-
proved prognostic ability to detect the risk of CVD or 
all- cause mortality.
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Systematic literature review 
 
Search terms used on PubMed and Embase (up to 18th October 2019): 
("muscle mass" or "skeletal muscle" or “sarcopenia” or "fat mass" or "body fat" or "body 
composition" or "fat free mass" or "lean mass" or "adiposity") AND ("mortality" or "death" 
or "survival" or "cardiovascular disease" or "CVD" or "stroke" or "coronary heart disease" or 
"congestive heart failure") 
Studies were excluded if they were done in patients or ill people (including but not limited to 
hospitalised, intensive care or dialysis patients, those with cancer, diabetes, COPD, CKD, 
dementia, HIV), done in children or adolescents, investigating a diet or exercise intervention, 
done in animals, molecular, cellular-level studies, or genetic studies. Only findings from 











Table S1. Summary of search findings. 
 
Exposure Outcome Sex 
    Number of associations identified in studies 







Combined men and women 7 8 3  
Men only 10 7 1 3 




Combined men and women 2 2 2  
Men only 7 2 1  




Combined men and women 7 2 3  
Men only 12 4 17 5 
Women only 13 10 19 3 
Fat mass CVD 
Combined men and women 2 1 10 3 
Men only 11 2 16  






Combined men and women   1  
Men only 2  2  






Combined men and women  1   
Men only         





Combined men and women   1  
Men only 1    





Combined men and women  1   
Men only         
Women only         
 
 
Each association assessed in the studies is counted distinctly (i.e. the number of associations exceeds the number of 
studies identified since some studies analysed more than one exposure/outcome combination). ‘Muscle mass’ includes 
studies that assessed measurements of lean mass from techniques such as bioimpedance analysis (BIA), dual energy x-ray 
absorptiometry (DEXA), mid upper arm circumference and calf circumference (it does not include studies of muscle quality 
such as grip strength). ‘Fat mass’ includes studies that assessed measurement of adiposity such as fat mass as determine by 
BIA or DEXA, percentage body fat, waist circumference, waist to hip ratio. Studies of BMI or body fat distribution indices 









Table S2. Systematic literature review. 
 
Reference 
Study name (date 
of recruitment) 
Study participants 
(location, N, age)  
Body composition 
measurement 
Exposure definition/coding Outcome  Shape of association  
68 
Abramowitz, et 
al. (2018)  
NHANES (1999-
2004) 
USA, n=11687 aged 
>20 yrs 
DEXA (Appendicular 
skeletal muscle mass) 
Low muscle defined as ASMI <5.45kg/m2 
(women) or <7.26kg/m2 (men) [2,3] 
All-cause 
mortality 
BMI and mortality: U (low muscle group), 0 (preserved muscle group) 
ASMI and mortality (men and women combined): - 
69 
Allison, et al. 
(2002) 
NHANES I & II  
USA, n=10169 men 
aged 25-75yrs 
Skinfolds (indicator of fat 
mass), upper arm 
circumference (fat free 




BMI and all-cause mortality: U (men) 
Fat free mass and mortality: linear - (men) 
Fat mass and mortality: linear + (men) 
70 
Andersen, et al. 
(2015) 
Shanghai Men's 






Waist to hip ratio Quintiles of WHR 
All-cause and 
CVD mortality 
WHR and mortality: linear + (men) 
 WHR and mortality: linear + (women) 
WHR and CVD mortality: linear + (men) 
WHR and CVD mortality:  linear + (women) 
71 










4 groups created: 
Optimal (MAMC >25.9cm and WC ≤102cm), 
sarcopenic (MAMC ≤25.9cm and WC 
≤102cm), sarcopenic obese (MAMC ≤25.9cm 






Sarcopenia and mortality: 0 (men) 
Sarcopenia and mortality: + (women) 
Sarcopenia and CVD: 0 (men) 
Sarcopenia and CVD:  + (women) 
72 
Bachettini et al. 
(2019) 
n/a 
Brazil, n=1291 aged 
>=60 years 
Using the European 
Working Group on 
Sarcopenia in Older People 





Severe sarcopenia and mortality: + (men and women combined) 
Other sarcopenia and mortality: 0 (men and women combined) 
 
73 







DEXA (Appendicular lean 
mass), lower limb strength 
Calculated ALM/height2 [2], ALM/BMI [1], 
ALM/weight*100 [12] from DEXA. Measured 
grip, lower-limb muscle, and upper-limb 
muscle strength and/or quality. 
Low muscle mass or function defined as 
participants in the lowest 20% of the sex-
specific distribution for each measurement 
Mortality, falls, 
fracture 
Muscle strength or quality and mortality (men and women combined): 0 
Low appendicular lean mass/BMI and mortality (men and women 
combined): + 
Low appendicular lean mass/height2 and mortality (men and women 
combined): 0 
Low appendicular lean mass/weight and mortality (men and women 
combined): 0 
74 




USA, n=4652 aged 
>60years 
BIA (skeletal muscle index, 
% body fat) 
4 definitions used: 
Normal if SMI ⩾10.76kg/m2 (men) 
>6.76kg/m2 (women);  
Class I sarcopenia if SMI 8.51–10.75 (men) 
5.76–6.75 (women);  
Class II sarcopenia: ⩽8.50 kg/m2 ⩽5.75 [17]. 
Obesity defined as body fat >27% (men) 
>38% (women) [3] 
All-cause 
mortality 
Sarcopenia only and mortality: 0 (men) 
Sarcopenia only and mortality: + (women) 
Sarcopenic obese and mortality: 0 (men) 
Sarcopenic obese and mortality: 0 (women) 
Obese only and mortality: 0 (men) 
Obese only and mortality: 0 (women) 
45 




USA, n=4984 aged 
>60 yrs 
DEXA (Appendicular lean 
mass), waist 
circumference, BMI 
Low lean mass defined as: ALM <19.75kg 
(men) <15.02kg (women) [1] or ALM:BMI 
<0.789 (men), <0.512 (women).  
Obesity defined as body fat >25% (men) 
>35% (women) [9].  
All-cause and 
CVD mortality 
Low lean mass and mortality: + (men) 
Low lean mass and mortality: 0 (women) 
Low lean mass and CVD: + (men) 
Low lean mass and CVD: 0 (women) 
Low lean mass with obesity and mortality: + (men) 
Low lean mass with obesity and mortality: 0 (women) 
Low lean mass with obesity and CVD : 0 (men)  
Low lean mass with obesity and CVD : 0 (women) 









Obesity (body fat %) and mortality: - (women) 
Obesity (body fat %) and CVD: 0 (men) 
Obesity (body fat %) and CVD:  0 (women) 
75 









DEXA (total body fat %, 
lean body mass %), BMI 
Quintiles of each exposure 
All-cause 
mortality 
Fat mass and mortality (women aged 50-59): linear +  
Fat mass and mortality (women aged >70): linear -  
Lean mass and mortality (women aged 50-59): linear –  
Lean mass and mortality (women aged >70): linear + 
76 
Bigaard, et al 
(2004) 





BIA (fat free mass index, 
body fat mass index) 
Modelled continuously using linear splines, 
and relative risks estimated per 10% 
increase in waist circumference and per 
kg/m2 increase in body fat mass index and 
fat free mass index 
Results stratified into high and low range 




Fat mass and mortality: J (men) 
Fat mass and mortality: J (women) 
Fat free mass and mortality: reverse J (men) 
Fat free mass and mortality: reverse J (women) 
WC and mortality: linear + (men) 
WC and mortality: linear + (women) 
77 
Bigaard, et al. 
(2005) 





BIA (body fat mass index, 
fat free mass index), waist 
circumference 
Modelled continuously using linear splines 
All-cause 
mortality 
Body fat mass index and all-cause mortality: J (men) 
 Body fat mass index and all-cause mortality: J (women) 
Fat free mass index and mortality: reverse J (men) 
 Fat free mass index and mortality: reverse J (women) 
78 
Boloukat, et al. 
(2018) 
Tehran Lipid and 
Glucose Study 
Iran, n=4631 aged 
>40yrs 
BMI, waist circumference, 
waist-to-height ratio, WHR 
Modelled continuously per 1 unit increase in 
each exposure 
CHD or stroke 
incidence 
WC and CVD: 0 (men) 
WC and CVD: 0 (women) 
WHR and CVD: 0 (men) 
WHR and CVD: 0 (women) 
Waist-to-height ratio and CVD: 0 (men) 
Waist-to-height ratio and CVD: 0 (women) 
43 




USA, n=4425 aged 
>60 yrs 
BIA (skeletal muscle 
index), gait speed 
Sarcopenia defined as low gait speed 
(<0.8m/s) and SMI <10.76 (men), <6.75 
(women)                                                                                                                                                                                                                                                                                                                                                       
All-cause and 
CVD mortality 
Sarcopenia and mortality: + (men) 
Sarcopenia and mortality: + (women) 
Sarcopenia and CVD: 0 (men) 
Sarcopenia and CVD: + (women) 
79 




USA, n=1487 aged 
>65 yrs 
BIA (Appendicular lean 
mass) 
Modelled continuously per 1 SD of ALM 
All-cause 
mortality 
Appendicular lean mass and mortality: - linear (men) 
Appendicular lean mass and mortality: - linear (women) 
44 








(muscle density, muscle 
area, fat area) 




Muscle area and mortality (men and women combined): 0 
Fat area and mortality (men and women combined): 0 
80 







BMI, body fat %, waist 
circumference 
7 groups for each exposure, and BMI per 
5kg/m2, % body fat per 10%, waist 
circumference per 1 SD 




BMI and stroke/haemorrhage (men and women combined): + linear  
WC and stroke/haemorrhage (men and women combined): + linear 
Body fat % and stroke/haemorrhage (men and women combined):  + 
linear 
81 






women with normal 
BMI 
DEXA - % whole body and 
regional fat quartiles, fat 
mass index (dividing total 
or regional fat mass in kg 
by height squared) 
Quartiles CVD 
Whole body fat mass and mortality: 0 (women) 
Leg fat and mortality: - (women) 
trunk fat and mortality: + (women) 
 
82 




USA, n=2841 aged 
>65yrs 
DEXA (Appendicular lean 
mass) 
Calculated ALM, ALM/BMI, ALM/H2 from 
DEXA. Sarcopenia defined using cut-points 
for each measure (given in their 
supplementary index).  
All-cause 
mortality 
Low appendicular lean mass and mortality: + (men and women 
combined) 
83 





n=1578 aged >65yrs 
DEXA (Appendicular 
skeletal muscle mass) 
Sarcopenia defined as ASM/weight <1 SD 
below the gender-specific mean of a 
reference group aged 20-39 years. Equates 
to <32.2% men, <25.6% women.  









Sarcopenic obesity if both sarcopenic and 
obese BMI 
84 
Chuang, et al. 
(2014) 
Elderly Nutrition 
and Health Survey 
(1999-2000) 
Taiwan, n=1512 
aged  >65yrs 
BIA (skeletal muscle mass 
index), BMI, waist 
circumference 
Low/high risk groups defined as ASMI 
<11.45kg/m2 (men) 8.51kg/m2 (women)  
based off quartiles 
All-cause 
mortality 
Low skeletal muscle index and mortality: 0 (men)  
Low skeletal muscle index and mortality: + (women) 
Low skeletal muscle index and CVD: 0 (men)  
Low skeletal muscle index and CVD: + (women) 
85 
Chuang, et al. 
(2016) 
Elderly Nutrition 
and Health Survey 
Taiwan, n=1485 
aged >65 yrs 
BIA (skeletal muscle mass 
index) 
Sarcopenia defined as SMMI men <11.45, 
women <8.51 [14] 
Sarcopenic obesity defined as being 
sarcopenic and having a high triglyceride 
(>150mg/dL) and high waist circumference 
(>90cm men, >80cm women) 
All-cause and 
CVD mortality 
Abdominal obesity and mortality: 0 (men and women combined) 
Abdominal obesity and CVD: 0 (men and women combined) 
Sarcopenic and mortality: 0 (men and women combined) 
Sarcopenic and CVD: 0 (men and women combined) 
Sarcopenic obesity and mortality: + (men and women combined) 
Sarcopenic obesity and CVD: + (men and women combined) 
86 
de Almeida 
Roediger, et al. 
(2019) 
SABE (2000-2010) 
Brazil, n=1504 aged 
>60yrs 
BMI, waist circumference, 
wait-to-hip ratio skinfold, 
mid-upper arm 
circumference, calf 
circumference, arm muscle 
area 
All exposures analysed as binary variables as 




WC and mortality: 0 (men and women combined) 
WHR and mortality: 0 (men and women combined) 
MAMC (muscle) and mortality: - (men and women combined) 
Calf circumference (muscle) and mortality: - (men and women 
combined) 
87 
de Santana et 
al. (2019) 
n/a 
Brazil, n=839 aged 
>=65yrs 
DEXA (total fat, 
appendicular lean mass) 





Low muscle and CVD mortality: + (men and women combined) 
Low muscle and mortality: + (men and women combined) 
Fat mass and CVD mortality: + (men and women combined) 
Fat mass and mortality: + (men and women combined) 
 
88 






women aged >65 
BIA (lean mass, fat mass, % 
body fat), BMI, waist girth 
Quintiles of each exposure 
All-cause 
mortality 
Fat mass and mortality (women): U 
Lean mass and mortality (women): 0 
BMI and mortality (women): U 
89 




USA, n=16415) aged 
18-89yrs 
BIA (body fat %), WHR 
Body fat % and WHR modelled continuously 
using cubic splines at 4 knots. 




Body fat % and mortality: U (men) 
Body fat % and mortality : U (women) 
WHR and mortality: U (men) 
WHR and mortality: + linear (women) 
90 
Gale, et al. 
(2007) 
n/a 
UK, n=800 aged  
>65yrs 
Skinfolds (fat mass, fat free 
mass), BMI, grip strength 




Body fat % and CVD: 0 (men)  
Body fat % and CVD: 0 (women) 
Body fat % and mortality: 0 (men) 
Body fat % and mortality: 0 (women) 
MAMC (muscle) and CVD: 0 (men) 
MAMC (muscle) and CVD: 0 (women) 
Fat free mass and CVD: 0 (men) 
Fat free mass and CVD: 0 (women) 
MAMC (muscle) and mortality: 0 (men) 
MAMC (muscle) and mortality: 0 (women) 
Fat free mass and mortality: 0 (men) 
Fat free mass and mortality: 0 (women) 
Grip strength and CVD: + (men) 
Grip strength and CVD: 0 (women) 
Grip strength and mortality: + (men) 
Grip strength and mortality:  0 (women) 
91 
Gillum, et al. 
(2001) 
NHANES I (1992) 
USA, n=6936 aged 
45-74yrs 
BMI, Subscapular skinfold 
(SSF), subscapular to 
triceps skinfold thickness 
ratio (SFR) 
Each exposure modelled in quartiles and 




Trunk obesity and stroke: weak U (white men ex-smokers)  
Trunk obesity and stroke: 0 (women) 
Overall obesity and stroke: U (white men ex-smokers) 
Overall obesity and stroke: 0 (women) 
92 




Mexico, n=159,755  
aged 35 to <75 





BMI and mortality: J (men and women cobined) 









WC and mortality: + (men and women combined) 
 
93 





BIA (fat mass index, fat 
free mass index) 
Quartiles of FMI and FFMI 
All-cause 
mortality 
Fat free mass index and mortality: 0 (women) 
Fat free mass index and mortality: - (men) 
Fat mass index and mortality: 0 (men) 
Fat mass index and mortality: 0 (women) 
94 




Study on Health 
and Aging 
South Korea, n=877 
aged >65yrs 
BIA (lean mass, fat mass, 
fat percentage, lean mass 
index), BMI, waist 
circumference 
3 groups for each exposure: <25th 




Lean mass and mortality: - (men and women combined) 
Fat mass and mortality: 0 (men and women combined) 
95 
Heitmann, et al. 
(2000) 
n/a 
Sweden, n=787 men 
aged 60yrs 
Whole body potassium 
counter (lean body mass 
and fat mass calculated) 
Quintiles, fractional polynomials 
All-cause 
mortality 
Fat free mass and mortality: reverse J (men) 
Fat mass and mortality: J (men) 
BMI and mortality: U (men) 
96 
Hirani, et al. 
(2017) 
Concord Health 




men aged >70yrs 
DEXA (Appendicular lean 
mass, fat %) 
Low lean mass defined as ALM:BMI ratio 
<0.789 [6],  
Obesity defined as fat % > 30% [7].  
4 groups created: neither obese nor low 







Obesity and mortality (men): 0 
Low muscle and mortality (men): 0 
Sarcopenic obesity and mortality (men): 0 
97 






BMI, Waist circumference, 
waist to hip ratio 
Quartiles of WC and WHR. 





Adiposity and incident CHD: + (men) 
Adiposity and incident CHD: + (women) 
Adiposity and mortality: +  (men) 
Adiposity and mortality: + (women) 
Adiposity and CHD mortality: 0 (men) 
Adiposity and CHD mortality: 0 (women) 
98 
Howell, et al. 
(2018) 





aged >20yrs  
BIA (lean mass, fat mass, 
body fat %), waist 
circumference, waist-to-
height ratio, skinfolds 
Modelled continuously: BMI per 5kg/m2, WC 
per 5cm, Waist to height ratioper 0.5, 
skinfolds per 5mm, % body fat per 5%, lean 
mass per 5kg, fat mass per 5kg 
All-cause and 
CVD mortality 
Fat mass and CVD mortality: - (men) 
Fat mass and CVD mortality: + (women) 
Fat mass and mortality: 0 (men) 
Fat mass and mortality: + (women) 
Lean mass and CVD mortality: 0 (men) 
Lean mass and CVD mortality: + (women) 
Lean mass and mortality: 0 (men) 






UK, n=296535 aged 
40-69yrs 
BMI, waist-circumference, 
waist-to-hip ratio, BIA 
(body fat %) 
All exposures treated as continuous 
variables (BMI 22kg/m2 was referent value) 
CVD incidence 
BMI and CVD: J (men and women combined) 
WC and CVD: + linear (men and women combined) 
WHR and CVD: + linear (men and women combined) 
Body fat % and CVD: + linear (men and women combined) 
99 




USA, n=11437 aged 
18-64 yrs 
BMI, waist circumference, 
waist-to-hip ratio, waist-
to-height ratio 
Modelled continuously per 1 SD increase in 
each exposure and also in quartiles 
All-cause 
mortality 
WC and all-cause mortality: + (men) 
WC and all-cause mortality: + (women) 
WHR and all-cause mortality: + (men) 
WHR and all-cause mortality: + (women) 
Waist-to-height ratio and all-cause mortality: + (men) 


















WC and all-cause mortality: J (men) 
WC and all-cause mortality: linear + (women) 
Skinfolds (adiposity) and mortality: J (men), 
Skinfolds (adiposity) and mortality: linear + (women) 
BMI and mortality: J (men) 
BMI and mortality: linear + (women) 
101 




UK, n=403199 aged 
40-69 yrs 
Grip strength, BMI, waist 
circumference, % body fat 
Per 5kg increase in GS, quintiles of GS within 




Grip strength and all-cause mortality: linear – (men) 
Grip strength and all-cause mortality: linear – (women) 
Grip strength and CVD mortality: linear – (men) 














USA, n=3754 aged 
65-100yrs 
BIA (fat free mass, fat 
mass) BMI, waist 
circumference, waist to hip 




Fat mass and stroke or CHD: 0 (men) 
Fat mass and stroke or CHD: 0 (women) 
Fat free mass and stroke or CHD: 0 (men) 
Fat free mass and stroke or CHD: 0 (women) 
WC and stroke: 0 (men) 
WC and stroke: 0 (women) 
WHR and stroke: 0 
WC and CHD: + 
WHR and CHD: + 
103 




Greece, n=10428  
Lean mass index and fat 
mass index created 
through total body lean 
and fat mass (indirectly 
calculated through 
population formals based 
on body weight, height, 
waist circumference) 
divided by height squared 
Tertiles CVD 
Fat mass and CVD: + (men) 
Fat mass and CVD: + (women) 
Lean mass and CVD: U (men) 
Lean mass and CVD: U (women) 
 





USA, n=38006 men 
aged 40-75 years 
Derived predicted lean 
body mass and fat mass 
using equations developed 
by NHANES and based on 
age, race, height, weight, 
waist circumference 







BMI & all-cause mortality: J (men) 
Fat mass & all-cause mortality: linear (men) 
Lean mass & all-cause mortality: U (men) 
Fat & CVD: linear (men) 
Lean body mass & CVD: weak U (men) 
BMI & CVD: U (men) 
104 
Lee, et al. 
(2012) 
n/a 
China, n=3978 aged 
>65yrs 
DEXA (body fat %), waist 
circumference, waist to hip 
ratio, relative abdominal 





All-cause mortality and % body fat: - (men) 
All-cause mortality and % body fat: 0 (women) 
All-cause mortality and waist circumference: 0 (men) 
All-cause mortality and waist circumference: 0 (women) 
All-cause mortality and WHR: 0 (men) 
All-cause mortality and WHR: 0 (women) 
CVD mortality and WC: 0 (men) 
CVD mortality and WC: 0 (women) 
CVD mortality and % body fat: 0 (men) 
CVD mortality and % body fat: 0 (women) 
CVD mortality and WHR: 0 (men) 
CVD mortality and WHR: 0 (women) 
105 




Cohort and the 




BMI, waist circumference, 
waist to hip ratio, waist to 
height ratio 





WC and CVD: linear + (men) 
WC and CVD: linear + (women) 
WHR and CVD: + (men)  
WHR and CVD: 0 (women) 
Waist-to-height ratio and CVD: + linear (men) 
Waist-to-height ratio and CVD: + linear (women) 
106 Li, et al. (2018) 
NHANES (1999-
2002) 
USA, n=4449 aged 
>50 yrs 
DEXA (Appendicular lean 
mass) 
Low muscle mass defined as appendicular 
lean mass (ALM) <19.75kg (M) or <15.02kg 
(F) and ALM/BMI <0.512 (M) and <0.789kg 
(F). Based on FNISH Sarcopenia Project 
definition [1]. Low muscle strength  
All-cause 
mortality 
Low muscle alone and mortality: 0 (men and women combined) 
Low muscle with low strength and mortality: + (men and women 
combined) 
107 




UK, n=15062 aged 
40-79yrs 




Body fat % and mortality: 0 (men) 
Body fat % and mortality: 0  (women) 
Body fat % and CVD: 0 (men) 














Iran, n=50,045 aged 
40-75 
BMI, waist circumference, 
waist to hip ratio, waist to 
height ratio 
Quintiles 
All cause and 
CVD mortality 
BMI and all-cause mortality: 0 (men) 
BMI and all-cause mortality: 0 (women) 
BMI and CVD mortality: + (men) 
BMI and CVD mortality: + (women) 
Waist to height ratioand mortality: + (men) 
Waist to height ratioand mortality: + (women) 
Waist to height ratioand CVD mortality: + (men) 
Waist to height ratioand CVD mortality: + (women) 
WC and mortality: 0 (men) 
WC and mortality 0 (women) 
WC and CVD mortality: + (men) 
WC and CVD mortality: + (women) 
WHR and mortality: + (men) 
WHR And mortality: + (women) 
WHR and CVD mortality: + (men) 
WHR and CVD mortality: + (women) 
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Newman, et al. 
(2006) 
Health, Aging and 
Body Composition 
study  
USA, n=29292 aged 
70-79yrs  
DEXA (leg and arm lean 
mass), CT scan (thigh 
muscle area), knee 
extension strength 
Per 1 SD increase 
All-cause 
mortality 
Arm or leg lean mass and mortality: 0 (men and women combined) 
Grip strength and mortality: + (men and women combined) 
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Ofstad et al 
(2019) 
HUNT 2 Norway, n=61,016  
BMI, WC, WHR, estimated 
total body fat (based on 
the YMCA's gender specific 
formulas), ABSI 
Quartiles CVD mortality 
Body fat (estimated) and CVD mortality: + (men) 
Body fat (estimated) and CVD mortality: + (women) 
WC and CVD mortality: + (men) 
WC and CVD mortality: + (women) 
BMI and CVD mortality: + 
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USA, n=60335 aged 
>20 years 
BMI, body fat % 
determined by hydrostatic 
weighing or skinfold 
measurements, fat mass 
index, fat free mass index, 
fat free mass 
For each exposure: very low <5th percentile, 
low 5-15th percentile, middle 15th-85th 
percentile, high 85-95th percentile, very 
high >95th  
CVD mortality 
BMI and CVD: + linear  (men and women combined) 
Body fat % and CVD: J (men and women combined) 
Fat mass index and CVD: J (men and women combined) 
Fat free mass and CVD: 0 (men and women combined) 
Fat free mass index and CVD: + (men and women combined) 
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Otsuka, et al 
(2018) 
Longitudinal 
Study of Aging 
(1997-2013) 
Japan, n=1978 aged 
40-79 yrs 
DEXA (Appendicular lean 
mass excluding bones [4]) 





Lean mass and mortality: 0 (men) 
Lean mass and mortality: 0 (women) 
112 






aged >40yrs (91% 
women) 
DEXA (body fat %), BMI 
Quintiles of BMI and body fat %. Fully 
adjusted models included both BMI and 
body fat % 
All-cause 
mortality 
BMI and mortality: U (men) 
BMI and mortality: U (women) 
Body fat % and mortality: J (men)  
Body fat % and mortality: reverse J (women) 
113 





n=7208 aged >50yrs 
DEXA (ASM, SMI) 
SMI normal >32% (men) >25.4% (women), 
class I sarcopenia 29-32% (men) 22.8-25.4% 
(women), class II sarcopenia <29% (men) 
<22.8% (women)  - corresponded to 1 and 2 
SDs below gender-specific means of 
younger population [18] 
CVD incidence 
Sarcopenia and CVD (men): + 
Sarcopenia and CVD (women): 0 
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index, waist circumference 
(WC), BMI, waist-to-height 
10 groups of each index 
All-cause and 
CVD mortality 
BMI and all-cause mortality: U (men and women combined) 
WC and all-cause mortality: U (men and women combined) 









ratio (WHR), a body shape 
index (ABSI) 
Weight-adjusted-waist index and all-cause mortality: U (men and 
women combined) 
ABSI and all-cause mortality: U (men and women combined) 
Weight-adjusted-waist index and CVD mortality: linear + (men and 
women combined) 
A Body Shape Index and CVD mortality: linear + (men and women 
combined) 
BMI and CVD: inverse J (men and women combined) 
WC and CVD: inverse J (men and women combined) 
WHR and CVD: inverse J (men and women combined) 
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USA, n=12,228 aged 
30-102ys 
Waist-to-thigh ratio, waist-
to-hip ratio, waist 
circumference, BMI 




WHR and mortality: linear + (men) 
WHR and mortality: 0 (women) 
Waist-to-height ratio and mortality: + linear (men) 
Waist-to-height ratio and mortality: + (women) 
BMI and mortality: U (men) 
BMI and mortality: U (women) 
WC and mortality: J (women) 
WC and mortality: J (men) 
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USA, n=5,780 aged 
30-64yrs 
BMI, waist circumference, 
waist to hip ratio, waist to 
thigh ratio 
Quartiles of each exposure, results stratified 
by sex and race (white/black) 
All-cause 
mortality 
BMI and all-cause mortality: 0 (men) 
BMI and all-cause mortality: 0 (women) 
WHR and all-cause mortality: linear + (women) 
WHR and all-cause mortality: 0 (men) 
Waist-to-thigh ratio and all-cause mortality: linear + (men) 
Waist-to-thigh ratio and all-cause mortality: linear + (women) 
WC and all-cause mortality: 0 (men) 
WC and all-cause mortality: 0 (women) 
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USA, n=16,164 men 
aged 40-84yrs 
Waist circumference, waist 
to hip ratio, BMI 
Quintiles of each exposure CHD 
WC and CVD: linear + (men) 
WHR and CVD: + linear (men) 
BMI and CVD: + linear (men) 
118 Sim et al (2019) 
Perth Longitudinal 
Study in Aging 
women 
Australia,  n=903 
older women 
DEXA (appendicular lean 
mass), BMI, grip strength, 
timed up and go 
Various definitions of sarcopenia. 
Foundation of National Institues of Health 
(FNIH), European Working Group on 
Sarcopenia in Older People (EWGSOP), and 
the adapted FNIH (AUS-POPF) using 
Australian population-specific cut points (<2 




Lean mass and mortality: 0 (women) 
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BIA (fat mass, body fat %), 
BMI, waist circumference, 




BMI and all-cause mortality: U (men)  
BMI and all-cause mortality: U (women) 
WC and all-cause mortality: linear + (men)  
WC and all-cause mortality: linear + (women) 
WHR and all-cause mortality: linear + (men) 
WHR and all-cause mortality: linear + (women) 
Fat mass and all-cause mortality: linear + (men) 
Fat mass and all-cause mortality: 0 (women) 
Body fat % and all-cause mortality: linear + (men) 
Body fat % and all-cause mortality: 0 (women) 
46 




USA, n=1355 aged 
>65yrs 
DEXA (Total, appendicular 
lean and fat mass) 
ALM, fat mass and lean principal 
components modelled linearly. Fat principal 




Appendicular lean mass and CVD: linear – (men and women combined) 
Appendicular lean mass and mortality: linear - (men and women 
combined) 
Fat mass and CVD: linear - (men and women combined) 














USA, n=3659 men 
aged >55 and 
women aged >65yrs 
BIA (SMI), non-muscle 
index (BMI - SMI) 
Quartiles of SMI 
All-cause 
mortality 







USA, n=6541 aged 
>20yrs 
DEXA (Appendicular 
skeletal muscle mass 
index, trunk fat mass 
index) 
4 groups: Low muscle/low fat 
(ASMI<median, TRFI<median), Low 
muscle/high fat (ASMI<median, 
TRFI>=median), High muscle/low fat 
(ASMI>=median, TRFI<median), high 




High muscle/low fat and CVD: - (men and women combined) 
High muscle/low fat and mortality: - (men and women combined) 
All other body composition groups and mortality: 0 (men and women 
combined) 
All other body composition group and CVD: 0 (men and women 
combined) 
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BMI, skinfolds (% body 
fat), waist circumference, 
waist to height ratio, waist 
to hip ratio 
Categorised as high or normal for each 
exposure. Cut-offs: Body fat 30%, Waist to 
hip ratio 0.75, waist to height ratio 0.5 
All-cause 
mortality 
Body fat % and all-cause mortality (women): 0 
WC and all-cause mortality (women): 0 
WHR and all-cause mortality  (women): 0 
Waist-to-height ratio and all-cause mortality (women): 0 
BMI and all-cause mortality (women): 0  




USA, n=2603 aged 
>60yrs 
Hydrostatic weighing or 
skinfolds (% body fat, fat 
mass, fat free mass), waist 
circumference, BMI 
BMI categories, WC categorised as 
abdominal obese if >88cm (men) or >102cm 
(women), % Body fat % categorised as obese 




WC and all-cause mortality: 0 (men and women combined) 
Body fat % and all-cause mortality: 0 (men and women combined) 
Fat free mass and all-cause mortality: + (men and women combined) 
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Israel, n=9151 men 
aged >23 ys 
BMI, Subscapular skinfold 
(SSF), subscapular to 
triceps skinfold thickness 
ratio (SFR) 
Exposures analysed per 1 SD increase 
Stroke and CHD 
mortality 
Trunk obesity and CVD mortality (men): 0 
Body fat distribution and CHD (men): + linear 









Abdominal obesity defined as waist 
circumference >94cm (men) or >80cm 
(women) 
CVD mortality WC and CVD mortality (men and women combined): 0 
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BMI, a body shape index, 
body adiposity index 
Quintiles of ABSI and WC, BMI groups 
All-cause 
mortality 
A Body Shape Index and CVD: linear + (women) 
BMI and CVD: U (women) 
Body adiposity index and CVD: U (women) 
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DEXA (fat and lean mass) Assessed continuously per kg  
All-cause 
mortality 
Lean mass and mortality: linear - (men) 
Lean mass and mortality: linear - (women) 
Fat mass and mortality: linear - (women) 
Fat mass and mortality: 0 (men) 
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USA, n=3577 aged 
>=50yrs 
DEXA 
Body composition phenotype (4 categories 
based on having low adiposity or high 
adiposity and low muscle mass or high 
muscle mass), Trunk FM/ASM ratio, Fat 
mass/fat free mass ratio. Then defined 
sarcopenic obese from cut-offs at various 
percentiles for each of these measures 
All cause 
mortality 
Sarcopenic obesity and mortality: + (men) aged 50 - 70 yr 
Sarcopenic obesity and mortality: + (women) aged 50 - 70 yr 
Sarcopenic obesity and mortality: 0 (men) aged > 70 yr 
Sarcopenic obesity and mortality: 0 (women) aged >70 yr 
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WC and total  stroke: + linear (men and women combined) 
WHR and total stroke: + linear (men and women combined) 








UK, n=4107 men 
aged 60-79 
Mid-upper arm 
circumference, mid arm 
muscle circumference, 
BMI, BIA (Fat mass index, 
fat free mass index) 
Quartiles of each exposure 
All-cause 
mortality 
Fat mass and mortality: 0 (men) 
Fat free mass and mortality: 0 (men) 















UK, n=4046 men 
aged 60-79yrs 
Mid-upper arm 
circumference, mid arm 
muscle circumference, BMI 
Tertiles of MAMC, and results stratified by 
prior CVD condition (none, coronary heart 
disease, heart failure) 
All-cause 
mortality 
MAMC (muscle) and CHD (men): linear - 
MAMC (muscle) and heart failure (men): 0 
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from 4 nursing 
homes 
SARC-F and SARC-CalF 
questionnaires to screen 
for sarcopenia.  




Sarcopenia and mortality: + (men and women combined) 
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Yuki, et al. 
(2017) 
Longitudinal 
Study of Aging 
(1997-2013) 
Japan, n=700 aged 
65-79yrs 
DEXA (skeletal muscle 
mass index), grip strength, 
gait speed 
Low muscle mass defined as SMI <7.0 
(men), <5.4 (women) [15]. Low grip strength 
defined as <26kg (men) <18kg (women) 
[15]. Low gait speed defined as <0.8m/s 
[15]. Sarcopenia if low SMI and one of low 
grip strength or low gait speed 
All-cause 
mortality 
Sarcopenia and mortality: + (men) 
Sarcopenia and mortality: 0 (women) 
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USA, n=876 frail 
women aged >65 
DEXA (Appendicular, 
central and total lean and 
fat mass) 
Quartiles of each measurement 
All-cause 
mortality 
Lean mass & mortality: 0 (women) 
Fat mass & mortality: linear - (women) 
134 








Waist to hip ratio Quintiles 
All-cause and 
CVD mortality 
WHR and mortality: linear + (women) 
WHR and CVD mortality: linear + (women) 
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Zhu, et al. 
(2003) 




Skinfolds (fat mass, fat free 
mass) 
All exposures analysed as continuous 
All-cause 
mortality 
BMI and mortality (women): U  
Fat free mass and mortality (women): linear -  
Fat mass and mortality (women): linear -  
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USA, n=9471 aged 
>20yrs 
DEXA (body fat % for 
whole-body, trunk, leg) 
Quartiles of each measure of FM% 
All-cause and 
CVD mortality 
Body fat % and CVD: U (men and women combined) 
Body fat % and all-cause mortality: U (men and women combined) 
Acronyms: ABSI: A body shape index; ASMI: Appendicular skeletal muscle mass index (appendicular skeletal muscle mass, kg/height2, m2); BAI: Body adiposity index; BIA: bioimpedance analysis; BFMI: Body fat mass index (= fat mass index); BMI: Body 
mass index (body mass, kg/ height2, m2); DEXA: Dual energy x-ray absorptiometry; FFM: Fat free mass; FFMI: Fat free mass index (fat free mass, kg/ height2, m2); FM: Fat mass; FMI: Fat mass index (fat mass, kg/ height2, m2); GS: Grip strength; KNHANES: 










Table S3. Derivation of variables used in analysis from the UK Biobank questionnaire and interviews. 
Covariate Categories used in analysis UK Biobank variable used (question ID) and source 




Quintiles of the residuals from the model of aSMM regressed 
on height 
Arm predicted mass (left) (UKBBID: 23126) ‡, arm predicted mass (right) (UKBBID: 23122) ‡, leg predicted mass (left) 
(UKBBID: 23118)‡, leg predicted mass (right) (UKBBID: 23114). 
Height (UKBBID: 12144) ‡. 
 




1. Low aSMM / low FM 
2. Low aSMM /  moderate FM 
3. Low aSMM / high FM 
4. Moderate aSMM / low FM 
5. Moderate aSMM / moderate FM 
6. Moderate aSMM / high FM 
7. High aSMM / low FM 
8. High aSMM / moderate FM 
9. High aSMM / high FM 
Tertiles of aSMM within tertiles of FM derived from: arm predicted mass (left) (UKBBID: 23126) ‡, arm predicted mass 
(right) (UKBBID: 23122) ‡, leg predicted mass (left) (UKBBID: 23118)‡, leg predicted mass (right) (UKBBID: 23114), 
Whole body fat mass (UKBBID: 23100)‡, Height (UKBBID: 12144) ‡. 
Low aSMM, residuals of aSMM regressed on height: -10.82 - ≤-0.97 (men), -5.88 - ≤ -0.57 (women) 
Moderate aSMM: residuals of aSMM regressed on height: -0.97- ≤ 0.85 (men), -0.57 - ≤ 0.45 (women) 
High aSMM: residuals of aSMM regressed on height: 0.85 - ≤ 14.50 (men), 0.46 - ≤ 11.99 (women) 
Low FM, kg: 5.0 - ≤ 18.1 (men), 5.0 - ≤ 21.4 (women) 
Moderate FM: 18.2 - ≤ 24.1 (men), 21.5 - ≤ 28.8 (women) 
High FM: 24.2 - ≤ 98.6 (men), 28.9 - ≤ 109.8 (women) 
BMI  Continuous (kg/m2) Body mass index (UKBBID: 21001)‡ 
Waist 
circumference 
Continuous (cm) Waist circumference (UKBBID: 48)‡ 
Grip strength Continuous (kg) Hand grip strength (left) (UKBBID: 46)‡, Hand grip strength (right) (UKBBID: 47)‡ 
Sociodemographic characteristics 
   
Sex Men 
Women 
Sex (UKBBID: 31)* 
Education Higher degree (college or university degree, or professional 
qualifications) 
Any school degree (A levels, AS levels, O levels, GCSEs or CSEs) 
Vocational qualifications (NVQ, HND or HNC) 
Other (none of the above qualifications) 
Qualifications (UKBBID: 6138)† 
Townsend index Quintiles (high index indicates most deprivation) Townsend index (UKBBID: 189)*  
Lifestyle factors 
Smoking status Never 
Current 
Previous 
Smoking status (UKBBID: 20116)† 
Alcohol intake None 
Occasional (<1 unit/week) 
Moderate (1-14 units/week) 
Heavy (>14 units/week) 
Alcohol intake frequency (UKBBID: 1558)† 
Depending on the participants’ response, they were asked how much they consumed per week or month of the 










Red wine (UKBBID: 4407, 1568)†; champagne and white wine (UKBBID: 4418, 1578)†; beer and cider (UKBBID: 4429, 








Beef intake (UKBBID: 1369)†, cheese intake (UKBBID: 1408)†, pork intake (UKBBID: 1389)†, lamb intake (UKBBID: 1379)†, 
processed meat intake (UKBBID: 1349), spread type (UKBBID: 1428)† 
The amount of each food eaten per week was totalled, then split into groups based off tertiles (with ‘none’ 








Fresh fruit intake (UKBBID: 1309)†, raw vegetable intake (UKBBID: 1299)†, cooked vegetable intake (UKBBID: 1289). 
The amount of each food eaten per week was totalled, then split into groups based off tertiles (with ‘none’ 
subsequently separated from the low category). 





Oily fish intake (UKBBID: 1329)† 








Number of days/week of vigorous physical activity 10+ minutes (UKBBID: 904)†; Duration of vigorous activity (UKBBID: 
914)† 
Number of days/week of moderate physical activity 10+ minutes (UKBBID: 884)†; Duration of moderate activity 
(UKBBID: 894)† 
Number of days/week walked 10+ minutes (UKBBID: 864)†; Duration of walks (UKBBID: 874)† 
Medical history  
Type 2 diabetes No 
Yes (if diagnosed by doctor or taking insulin for diabetes) 
Diabetes diagnosed by doctor (UKBBID: 2443)† 
Medication for cholesterol, blood pressure or diabetes (men) (UKBBID: 6177)†; Medication for cholesterol, blood 
pressure, diabetes, or take exogenous hormones (women) (UKBBID: 6153)†  
Hypertension No 
Yes (if diagnosed by doctor, had an SBP >140mmHg, DBP 
>90mmHg or taking medication for blood pressure) 
Vascular/heart problems diagnosed by doctor (high blood pressure is one response) (UKBBID: 6150)† 
Systolic blood pressure, automated reading / manual reading (UKBBID: 4080 / 93)‡ 
Diastolic blood pressure, automated reading / manual reading (UKBBID: 4079 / 94)‡ 
Medication for cholesterol, blood pressure or diabetes (men) (UKBBID: 6177)†; Medication for cholesterol, blood 
pressure, diabetes, or take exogenous hormones (women) (UKBBID: 6153)† 
Cholesterol  No 
Yes (if taking cholesterol-lowering medication) 
Medication for cholesterol, blood pressure or diabetes (men) (UKBBID: 6177)†; Medication for cholesterol, blood 
pressure, diabetes, or take exogenous hormones (women) (UKBBID: 6153)†; blood lipids (UKBBID: 30690,30760,30870) 
Prior cancer No 
Yes (if cancer had been previously diagnosed by a doctor) 
Cancer diagnosed by doctor (UKBBID: 2453)† 
Menopause No 
Yes (if responded to questions saying they have experienced 
the menopause) 












Table S4. Baseline characteristics of the study population according to appendicular skeletal muscle mass and fat mass quintiles. 
 
χ2 test for trend: p<0.05 for all characteristics across the aSMM and FM quintiles. All characteristics were determined at the baseline assessment clinic through touch-screen questionnaires, interviews and/or physical 
measurements. Higher education: college or university degree or professional qualifications. Low physical activity: <600 metabolic equivalent (MET)-minutes per week32 . Heavy alcohol drinker: >14 units of alcohol a week)137. 
Hypertension: systolic blood pressure >140mmHg, diastolic blood pressure >90mmHg, was diagnosed by a doctor or were taking medication to lower blood pressure. Diabetes and cholesterol: taking medication for these conditions 
or diagnosed by a doctor. Cancer history: diagnosed with cancer >5 years ago (those with more recent cancer had been excluded). Low fruit and vegetable intake: the lowest consumption tertile (< 21 portions per week). High 
saturated fat: the highest saturated fat tertile, based off portions per week of beef, lamb, pork and whether they consumed animal or plant-based spreads. Low oily fish: lowest consumption tertile (< 1 portion per week). 
 Men appendicular skeletal muscle mass (aSMM) quintiles, range (kg)  Men fat mass (FM) quintiles, range (kg)  Total 
 13.5 - ≤ 24.0 24.1 - ≤ 26.0 26.1 - ≤ 27.6 27.7 - ≤ 30.0 30.1 - ≤ 54.5  5.0 - ≤ 15.7 15.8 - ≤ 19.4 19.5 - ≤ 22.9 23.0 - ≤ 27.5 27.6 - ≤ 98.6   
Age at recruitment, mean (SD) 61.0 (6.4) 58.2 (7.4) 56.0 (7.8) 54.0 (7.9) 51.7 (7.8)  54.9 (8.3) 56.0 (8.2) 56.5 (8.1) 56.7 (8.0) 56.9 (7.8)  56.2 (8.1) 
aSMM (kg), mean (SD) 24.6 (2.9) 25.9 (2.8) 26.9 (2.9) 28.1 (3.0) 30.5 (3.6)  24.6 (2.7) 25.7 (2.7) 26.7 (2.7) 28.0 (2.8) 31.0 (3.6)  27.2 (3.7) 
FM (kg), mean (SD) 22.4 (7.1) 21.6 (7.2) 21.4 (7.4) 21.5 (7.8) 22.2 (9.2)  12.4 (2.4) 17.5 (1.1) 21.0 (1.0) 24.9 (1.3) 33.6 (6.2)  21.8 (7.8) 
Body mass index (BMI), mean (SD) 26.0 (3.5) 26.8 (3.5) 27.4 (3.6) 28.2 (3.8) 29.7 (4.4)  23.3 (1.8) 25.6 (1.6) 27.1 (1.6) 29.0 (1.8) 33.1 (3.5)  27.6 (4.0) 
Weight (kg), mean (SD) 81.1 (12.1) 83.0 (12.1) 84.9 (12.4) 87.3 (13.0) 92.6 (15.1)  71.7 (7.0) 78.7 (6.3) 84.0 (6.2) 90.3 (6.5) 104.3 (11.8)  85.8 (13.6) 
Height (cm), mean (SD) 176.6 (6.7) 175.9 (6.7) 175.8 (6.7) 176.0 (6.7) 176.6 (6.7)  175.3 (6.8) 175.5 (6.6) 176.0 (6.5) 176.6 (6.6) 177.6 (6.7)  176.2 (6.7) 
Higher education, n (%) 12740 (39.7) 13085 (40.7) 13140 (40.9) 13096 (40.7) 12645 (39.3)  13909 (43.1) 13669 (42.1) 12987 (40.6) 12406 (38.8) 11735 (36.7)  64706 (40.2) 
Current smokers, n (%) 3714 (11.6) 3431 (10.7) 3573 (11.1) 3563 (11.1) 3724 (11.6)  4366 (13.5) 3600 (11.1) 3368 (10.5) 3385 (10.6) 3286 (10.3)  18005 (11.2) 
Low fruit and vegetable intake, n (%) 14779 (46.0) 14122 (43.9) 13977 (43.5) 13996 (43.5) 13367 (41.6)  13624 (42.2) 13909 (42.8) 14191 (44.3) 14168 (44.3) 14349 (44.8)  70241 (43.7) 
High saturated intake, n (%) 11706 (36.4) 11786 (36.6) 11647 (36.2) 11637 (36.2) 11778 (36.6)  10457 (32.4) 11354 (34.9) 11699 (36.6) 12111 (37.9) 12933 (40.4)  58554 (36.4) 
Low oily fish intake, n (%) 10919 (34.0) 11292 (35.1) 11342 (35.3) 11807 (36.7) 11988 (37.3)  11197 (34.7) 11452 (35.2) 11518 (36.0) 11520 (36.0) 11661 (36.4)  57348 (35.7) 
Heavy drinkers, n (%) 19948 (62.1) 19885 (61.8) 19841 (61.7) 19608 (61.0) 18666 (58.1)  17562 (54.4) 19859 (61.1) 20297 (63.4) 20535 (64.2) 19695 (61.5)  97948 (60.9) 
Low physical activity, n (%) 7247 (22.6) 6670 (20.7) 6300 (19.6) 5901 (18.3) 5518 (17.2)  4580 (14.2) 5351 (16.5) 6030 (18.8) 6918 (21.6) 8757 (27.4)  31636 (19.7) 
Hypertension, n (%) 20146 (62.7) 18878 (58.7) 18102 (56.3) 17362 (54.0) 17370 (54.0)  12683 (39.3) 16508 (50.8) 18523 (57.9) 20600 (64.4) 23544 (73.5)  91858 (57.1) 
Type 2 diabetes, n (%) 1300 (4.1) 1250 (3.9) 1156 (3.6) 1191 (3.7) 1408 (4.4)  388 (1.2) 666 (2.1) 906 (2.8) 1462 (4.6) 2883 (9.0)  6305 (3.9) 
Cancer history (>5 years ago), n (%) 1176 (3.7) 927 (2.9) 816 (2.5) 662 (2.1) 652 (2.0)  780 (2.4) 836 (2.6) 856 (2.7) 872 (2.7) 889 (2.8)  4233 (2.6) 
Cholesterol medication, n (%) 6204 (19.5) 5171 (16.2) 4646 (14.6) 4145 (13.0) 3842 (12.0)  2175 (6.8) 3807 (11.8) 4664 (14.7) 5922 (18.6) 7440 (23.4)  24008 (15.0) 
              
 Women appendicular skeletal muscle mass (aSMM) quintiles, range (kg)  Women fat mass (FM) quintiles, range (kg)  Total 
 10.3 - ≤ 16.5 16.6 - ≤ 17.5 17.6 - ≤ 18.6 18.6 - ≤ 19.9 20.0 - ≤ 39.2  5.0 - ≤ 18.5 18.6 - ≤ 22.8 22.9 - ≤ 27.1 27.2 - ≤ 33.3 33.4 - ≤ 109.8   
Age at recruitment, mean (SD) 58.9 (7.0) 57.1 (7.6) 55.8 (7.9) 54.6 (8.0) 53.2 (8.1)  54.1 (8.1) 55.7 (8.0) 56.6 (7.9) 57.0 (7.7) 56.4 (7.8)  55.9 (8.0) 
aSMM (kg), mean (SD) 17.0 (1.7) 17.5 (1.7) 18.0 (1.8) 18.7 (1.9) 20.3 (2.5)  16.6 (1.5) 17.3 (1.4) 17.9 (1.4) 18.8 (1.5) 21.1 (2.3)  18.3 (2.3) 
FM (kg), mean (SD) 27.7 (8.5) 26.0 (8.4) 25.5 (8.8) 25.3 (9.5) 27.0 (11.9)  15.2 (2.6) 20.7 (1.2) 24.9 (1.3) 29.9 (1.7) 41.1 (7.4)  26.3 (9.6) 
Body mass index (BMI), mean (SD) 25.9 (4.2) 26.0 (4.2) 26.3 (4.4) 26.8 (4.8) 28.5 (6.0)  21.6 (1.7) 24.0 (1.5) 25.9 (1.7) 28.3 (2.0) 33.9 (4.3)  26.7 (4.9) 
Weight (kg), mean (SD) 69.1 (11.6) 68.8 (11.6) 69.4 (12.1) 70.8 (12.9) 75.9 (16.3)  56.4 (4.7) 63.2 (3.7) 68.5 (3.7) 75.3 (4.2) 90.9 (11.1)  70.8 (13.3) 
Height (cm), mean (SD) 163.4 (6.2) 162.6 (6.1) 162.5 (6.2) 162.6 (6.2) 163.3 (6.2)  161.6 (6.1) 162.5 (6.1) 162.9 (6.1) 163.3 (6.1) 164.0 (6.2)  162.9 (6.2) 
Higher education, n (%) 14330 (36.6) 15246 (38.9) 16033 (40.9) 16513 (42.2) 17056 (43.6)  18112 (45.5) 16503 (42.6) 15834 (39.8) 14520 (37.7) 14209 (36.4)  79178 (40.4) 
Current smokers, n (%) 3039 (7.8) 3164 (8.1) 3231 (8.2) 3258 (8.3) 3377 (8.6)  3792 (9.5) 3166 (8.2) 3151 (7.9) 3062 (8.0) 2898 (7.4)  16069 (8.2) 
Low fruit and vegetable intake, n (%) 12608 (32.2) 12333 (31.5) 11874 (30.3) 11521 (29.4) 10910 (27.9)  12125 (30.5) 11518 (29.7) 11756 (29.6) 11613 (30.2) 12234 (31.3)  59246 (30.3) 
High saturated intake, n (%) 11699 (29.9) 11407 (29.1) 11252 (28.7) 11485 (29.3) 11212 (28.6)  10415 (26.2) 10824 (27.9) 11615 (29.2) 11762 (30.6) 12439 (31.9)  57055 (29.1) 
Low oily fish intake, n (%) 12200 (31.2) 12678 (32.4) 12619 (32.2) 13034 (33.3) 13137 (33.6)  12971 (32.6) 12521 (32.3) 12669 (31.8) 12425 (32.3) 13082 (33.5)  63668 (32.5) 
Heavy drinkers, n (%) 12955 (33.1) 12840 (32.8) 13025 (33.2) 13134 (33.5) 12318 (31.5)  13562 (34.1) 13654 (35.2) 13525 (34.0) 12561 (32.6) 10970 (28.1)  64272 (32.8) 
Low physical activity, n (%) 10117 (25.8) 8974 (22.9) 8431 (21.5) 7986 (20.4) 7837 (20.0)  6398 (16.1) 7114 (18.4) 8288 (20.8) 9385 (24.4) 12160 (31.1)  43345 (22.1) 
Hypertension, n (%) 19371 (49.5) 17669 (45.1) 16440 (42.0) 15877 (40.5) 16330 (41.7)  11345 (28.5) 14192 (36.6) 17091 (43.0) 19293 (50.1) 23766 (60.9)  85687 (43.8) 
Type 2 diabetes, n (%) 635 (1.6) 673 (1.7) 669 (1.7) 805 (2.1) 1250 (3.2)  239 (0.6) 363 (0.9) 524 (1.3) 860 (2.2) 2046 (5.3)  4032 (2.1) 
Cancer history (>5 years ago), n (%) 2540 (6.5) 2298 (5.9) 2010 (5.1) 1933 (4.9) 1845 (4.7)  1912 (4.8) 2052 (5.3) 2278 (5.7) 2214 (5.8) 2170 (5.6)  10626 (5.4) 
Cholesterol medication, n (%) 4294 (11.0) 3605 (9.3) 3163 (8.1) 3015 (7.8) 3080 (7.9)  1536 (3.9) 2350 (6.1) 3349 (8.5) 4201 (11.0) 5721 (14.8)  17157 (8.8) 









Table S5. Baseline characteristics of the study population according to body composition groups. 
 
Men   
Low Muscle / 
Low Fat 
Med Muscle / 
Low Fat 
High Muscle / 
Low Fat 
Low Muscle / 
Med Fat 
Med Muscle / 
Med Fat 
High Muscle / 
Med Fat 
Low Muscle / 
High Fat 
Med Muscle / 
High Fat 
High Muscle / 
High Fat 
Age at recruitment, mean (SD) 59.0 (7.3) 55.1 (8.0) 51.7 (8.0) 60.3 (6.7) 56.3 (7.7) 52.6 (8.0) 60.7 (6.5) 56.7 (7.6) 53.2 (7.8) 
Appendicular skeletal muscle (kg), mean (SD) 22.9 (2.1) 24.9 (1.9) 27.1 (2.3) 24.5 (1.9) 26.6 (1.8) 29.1 (2.2) 27.3 (2.6) 29.6 (2.5) 32.7 (3.3) 
Fat mass (kg), mean (SD) 14.6 (2.8) 14.3 (2.8) 13.8 (3.1) 21.0 (1.7) 21.0 (1.7) 21.0 (1.7) 29.8 (5.5) 30.0 (5.8) 31.3 (7.2) 
Body mass index (BMI), mean (SD) 22.8 (1.6) 24.1 (1.6) 25.4 (1.8) 25.7 (1.3) 27.2 (1.2) 28.6 (1.4) 29.7 (2.8) 31.4 (2.9) 33.5 (3.6) 
Weight, mean (SD) 70.3 (6.3) 74.0 (6.3) 78.3 (7.0) 79.7 (5.3) 83.8 (5.1) 88.8 (5.9) 93.6 (9.7) 98.4 (10.0) 105.4 (12.3) 
Height, mean (SD) 175.4 (6.8) 175.1 (6.7) 175.5 (6.7) 176.1 (6.6) 175.7 (6.5) 176.2 (6.6) 177.4 (6.6) 177.0 (6.6) 177.3 (6.7) 
Higher education, n (%)  7753 (42.8) 7814 (43.2) 7626 (42.1) 7240 (41.0) 7309 (41.3) 6949 (39.3) 6488 (36.4) 6760 (37.9) 6767 (38.0) 
Current smokers, n (%)  2406 (13.3) 2139 (11.8) 2285 (12.6) 1850 (10.5) 1882 (10.6) 1951 (11.0) 1768 (9.9) 1823 (10.2) 1901 (10.7) 
Low fruit and vegetable intake, n (%)  8143 (45.0) 7708 (42.6) 7199 (39.8) 7903 (44.7) 7827 (44.3) 7593 (42.9) 8095 (45.5) 7900 (44.3) 7873 (44.2) 
High saturated intake, n (%)  6078 (33.6) 6014 (33.2) 6006 (33.2) 6423 (36.4) 6406 (36.2) 6510 (36.8) 6978 (39.2) 7064 (39.6) 7075 (39.7) 
Low oily fish intake, n (%)  6141 (33.9) 6302 (34.8) 6510 (36.0) 5948 (33.7) 6296 (35.6) 6698 (37.9) 6280 (35.3) 6539 (36.7) 6634 (37.2) 
Heavy drinkers, n (%)  10276 (56.8) 10373 (57.3) 10233 (56.5) 11242 (63.6) 11271 (63.7) 10997 (62.2) 11508 (64.7) 11370 (63.8) 10498 (58.9) 
Low physical activity, n (%)  3250 (18.0) 2669 (14.7) 2204 (12.2) 3657 (20.7) 3413 (19.3) 2993 (16.9) 4695 (26.4) 4475 (25.1) 4280 (24.0) 
Hypertension, n (%) 8641 (47.7) 7727 (42.7) 7208 (39.8) 10898 (61.7) 10187 (57.6) 9600 (54.3) 12947 (72.7) 12437 (69.8) 12213 (68.6) 
Diabetes, n (%) 298 (1.6) 245 (1.4) 274 (1.5) 558 (3.2) 505 (2.9) 500 (2.8) 1233 (6.9) 1245 (7.0) 1447 (8.2) 
Cholesterol medication, n (%) 1930 (10.7) 1505 (8.4) 1195 (6.7) 3179 (18.1) 2527 (14.4) 2093 (11.9) 4515 (25.5) 3723 (21.0) 3341 (18.9) 
Cancer diagnosed by doctor (>5 years ago), n (%) 573 (3.2) 407 (2.3) 373 (2.1) 591 (3.3) 480 (2.7) 340 (1.9) 651 (3.7) 468 (2.6) 350 (2.0)           
 
Women  
Low Muscle / 
Low Fat 
Med Muscle / 
Low Fat 
High Muscle / 
Low Fat 
Low Muscle / 
Med Fat 
Med Muscle / 
Med Fat 
High Muscle / 
Med Fat 
Low Muscle / 
High Fat 
Med Muscle / 
High Fat 
High Muscle / 
High Fat 
Age at recruitment, mean (SD) 57.1 (7.7) 54.6 (8.0) 52.2 (7.9) 58.7 (7.1) 56.6 (7.8) 54.4 (8.1) 58.7 (7.1) 56.5 (7.7) 54.7 (8.0) 
Appendicular skeletal muscle (kg), mean (SD) 15.7 (1.0) 16.7 (1.0) 18.0 (1.3) 16.7 (1.0) 17.8 (0.9) 19.2 (1.2) 18.7 (1.5) 20.0 (1.5) 22.1 (2.3) 
Fat mass (kg), mean (SD) 17.8 (2.8) 17.1 (3.1) 16.4 (3.4) 25.1 (2.1) 24.9 (2.1) 24.9 (2.1) 36.1 (6.7) 36.3 (6.9) 38.8 (8.8) 
Body mass index (BMI), mean (SD) 21.8 (1.7) 22.5 (1.8) 23.1 (1.9) 24.9 (1.6) 25.9 (1.6) 26.9 (1.8) 30.0 (3.5) 31.5 (3.7) 34.0 (4.7) 
Weight, mean (SD) 56.8 (4.4) 58.6 (4.8) 60.9 (5.3) 66.1 (3.6) 68.4 (3.6) 71.5 (4.0) 80.9 (9.2) 84.0 (9.5) 90.9 (12.6) 
Height, mean (SD) 161.6 (6.2) 161.6 (6.1) 162.5 (6.1) 163.1 (6.1) 162.6 (6.1) 163.1 (6.2) 164.2 (6.2) 163.5 (6.1) 163.6 (6.2) 
Higher education, n (%) 9086 (41.3) 9855 (44.8) 10384 (47.2) 8069 (37.2) 8681 (39.9) 9277 (42.7) 7548 (35.0) 7976 (37.0) 8302 (38.5) 
Current smokers, n (%)  1977 (9.0) 1946 (8.8) 2027 (9.2) 1652 (7.6) 1721 (7.9) 1795 (8.3) 1596 (7.4) 1618 (7.5) 1737 (8.1) 
Low fruit and vegetable intake, n (%)  7248 (33.0) 6664 (30.3) 6047 (27.5) 6700 (30.9) 6491 (29.9) 6072 (28.0) 6863 (31.8) 6737 (31.2) 6424 (29.8) 
High saturated intake, n (%)  5875 (26.7) 5960 (27.1) 5867 (26.7) 6416 (29.5) 6303 (29.0) 6340 (29.2) 6864 (31.8) 6720 (31.2) 6710 (31.1) 
Low oily fish intake, n (%)  6984 (31.8) 7159 (32.5) 7342 (33.4) 6680 (30.8) 6845 (31.5) 7228 (33.3) 6969 (32.3) 7150 (33.1) 7311 (33.9) 
Heavy drinkers, n (%)  7167 (32.6) 7649 (34.8) 7893 (35.9) 7415 (34.1) 7400 (34.0) 7428 (34.2) 6840 (31.7) 6542 (30.3) 5752 (26.7) 
Low physical activity, n (%)  4468 (20.3) 3679 (16.7) 2965 (13.5) 4922 (22.7) 4536 (20.9) 4116 (19.0) 6478 (30.0) 6130 (28.4) 6051 (28.1) 
Hypertension, n (%) 7938 (36.1) 6817 (31.0) 5918 (26.9) 9983 (46.0) 9342 (43.0) 8681 (40.0) 12572 (58.3) 11981 (55.5) 12455 (57.8) 
Diabetes, n (%) 155 (0.7) 138 (0.6) 175 (0.8) 247 (1.1) 285 (1.3) 362 (1.7) 626 (2.9) 786 (3.7) 1258 (5.9) 
Cholesterol medication, n (%) 1357 (6.2) 979 (4.5) 695 (3.2) 2057 (9.5) 1829 (8.5) 1607 (7.5) 3079 (14.4) 2720 (12.7) 2834 (13.3) 
Cancer diagnosed by doctor (>5 years ago) , n (%) 1270 (5.8) 1077 (4.9) 932 (4.2) 1433 (6.6) 1173 (5.4) 1092 (5.0) 1358 (6.3) 1175 (5.5) 1116 (5.2) 
Menopause, n (%) 14788 (67.3) 12378 (56.3) 9432 (42.9) 15674 (72.2) 13585 (62.5) 11126 (51.2) 15109 (70.1) 13077 (60.6) 10896 (50.6) 
All characteristics were determined at the baseline assessment clinic through touch-screen questionnaires, interviews and/or physical measurements. Higher education: has a college or university degree or professional 
qualifications. Low physical activity: <600 metabolic equivalent (MET)-minutes per week32. Heavy alcohol drinker: drinking >14 units of alcohol a week137). Hypertension: if participants had a systolic blood pressure >140mmHg, 
diastolic blood pressure >90mmHg, had been diagnosed by a doctor or were taking medication to lower blood pressure. Diabetes and high cholesterol: participants were taking medication for these conditions or diagnosed by a 
doctor. Cancer history: diagnosed with cancer >5 years ago (those with more recent cancer had been excluded). Low fruit and vegetable intake: the lowest consumption tertile (< 21 portions per week). High saturated fat: the 









Table S6. Partial correlation coefficients between appendicular skeletal muscle mass, fat 











Men  aSMM FM Height 
    aSMM - 0.7132 0.5185 
    FM 0.7132 - 0.1375 
    Height 0.5185 0.1375 - 
Women  aSMM FM Height 
     aSMM - 0.7771 0.4403 
     FM 0.7771 - 0.1544 









Table S7. CVD sequential model adjustment. 
 




Test for non-linearity across quintiles conducted using LRTs with 4df (p<0.05 indicates significant departure from linearity). Adjusted hazard ratios 
(HR) and 95% confidence intervals (CI) obtained using Cox proportional hazard regression. Age at risk adjusted for by using age during study as the 
underlying timescale for Cox regression. Height adjusted for by inclusion as continuous variable for FM and by regression out of variation due to 
height for ASM.  *Sociodemographic characteristics: Townsend index of deprivation, education. †Lifestyle factors: smoking status, alcohol intake, 
physical activity, oily fish intake, fruit and vegetable intake, saturated fat intake. ‡Medical history: diabetes, cancer history, menopause (women). 2 











 + Lifestyle factors† 
 + Medical 
history‡ 
  + Mutual 
adjustment for 
ASM or FM 
Appendicular skeletal muscle mass (aSMM) 
Men 1 4373 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
  2 3715 0.99 (0.95 - 1.03) 1.00 (0.96 - 1.04) 1.01 (0.97 - 1.06) 1.01 (0.97 - 1.06) 1.02 (0.97 - 1.06) 
  3 3385 1.03 (0.98 - 1.08) 1.04 (1.00 - 1.09) 1.06 (1.01 - 1.11) 1.06 (1.01 - 1.11) 1.07 (1.02 - 1.12) 
  4 3055 1.07 (1.02 - 1.12) 1.08 (1.03 - 1.14) 1.11 (1.06 - 1.16) 1.10 (1.05 - 1.15) 1.10 (1.05 - 1.16) 
  5 2971 1.25 (1.19 - 1.31) 1.26 (1.20 - 1.32) 1.29 (1.23 - 1.35) 1.27 (1.21 - 1.33) 1.25 (1.19 - 1.31) 
  Non-linearity p-value p<0.001 p<0.001 p<0.001 p<0.001 0.014 
 2 103 106 120 106 87 
Women 1 2617 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
 2 2182 0.92 (0.87 - 0.97) 0.93 (0.88 - 0.98) 0.93 (0.88 - 0.99) 0.93 (0.88 - 0.98) 0.95 (0.90 - 1.01) 
 3 1848 0.85 (0.80 - 0.91) 0.87 (0.82 - 0.92) 0.87 (0.82 - 0.93) 0.87 (0.82 - 0.92) 0.89 (0.84 - 0.95) 
 4 1753 0.89 (0.83 - 0.94) 0.90 (0.85 - 0.96) 0.91 (0.86 - 0.97) 0.90 (0.85 - 0.96) 0.92 (0.87 - 0.98) 
 5 1885 1.08 (1.02 - 1.15) 1.09 (1.03 - 1.16) 1.09 (1.03 - 1.16) 1.06 (1.00 - 1.13) 1.03 (0.97 - 1.09) 
  Non-linearity p-value p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 
 2 69 63 59 51 26 
Fat mass (FM) 
Men 1 2565 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
  2 3097 1.14 (1.08 - 1.20) 1.14 (1.08 - 1.20) 1.15 (1.09 - 1.21) 1.14 (1.09 - 1.21) 1.16 (1.10 - 1.22) 
  3 3393 1.25 (1.19 - 1.31) 1.24 (1.18 - 1.31) 1.25 (1.19 - 1.32) 1.24 (1.18 - 1.31) 1.26 (1.20 - 1.33) 
  4 3835 1.42 (1.35 - 1.49) 1.40 (1.33 - 1.47) 1.40 (1.33 - 1.48) 1.38 (1.31 - 1.45) 1.40 (1.33 - 1.47) 
  5 4609 1.76 (1.68 - 1.85) 1.71 (1.63 - 1.79) 1.71 (1.62 - 1.79) 1.65 (1.57 - 1.73) 1.65 (1.57 - 1.73) 
  Non-linearity p-value p<0.001 0.002 0.005 0.024 0.081 
 2 654 571 638 455 453 
Women 1 1313 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
 2 1653 1.16 (1.08 - 1.25) 1.15 (1.07 - 1.24) 1.16 (1.08 - 1.25) 1.16 (1.08 - 1.24) 1.16 (1.08 - 1.25) 
 3 2037 1.32 (1.23 - 1.42) 1.30 (1.21 - 1.39) 1.31 (1.22 - 1.40) 1.30 (1.21 - 1.39) 1.31 (1.22 - 1.40) 
 4 2357 1.56 (1.46 - 1.67) 1.51 (1.41 - 1.62) 1.51 (1.41 - 1.62) 1.49 (1.39 - 1.59) 1.50 (1.40 - 1.61) 
 5 2925 2.07 (1.94 - 2.21) 1.97 (1.84 - 2.10) 1.95 (1.82 - 2.08) 1.88 (1.76 - 2.01) 1.88 (1.76 - 2.01) 
 Non-linearity p-value p<0.001 p<0.001 0.003 0.016 0.038 









Table S8. Mortality sequential model adjustment. 
 
Hazard ratios of all-cause mortality associated with appendicular skeletal muscle mass (aSMM) 
and fat mass (FM)  
 
  
Quintile  No. events 




 + Lifestyle factors† 
 + Medical 
history‡ 
  + Mutual 
adjustment for 
ASM or FM 
Appendicular skeletal muscle mass (aSMM) 
Men 1 2706 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
  2 2013 0.94 (0.88 - 0.99) 0.95 (0.90 - 1.01) 0.97 (0.92 - 1.03) 0.97 (0.92 - 1.03) 0.98 (0.92 - 1.04) 
  3 1673 0.94 (0.88 - 1.00) 0.96 (0.90 - 1.02) 0.99 (0.93 - 1.05) 0.99 (0.93 - 1.05) 0.99 (0.93 - 1.06) 
  4 1378 0.94 (0.88 - 1.00) 0.96 (0.89 - 1.02) 1.00 (0.93 - 1.07) 0.99 (0.93 - 1.06) 1.00 (0.93 - 1.06) 
  5 1312 1.12 (1.05 - 1.20) 1.13 (1.06 - 1.21) 1.19 (1.11 - 1.27) 1.17 (1.09 - 1.25) 1.16 (1.08 - 1.24) 
  Non-linearity p-value p<0.001 p<0.001 p<0.001 p<0.001 0.002 
 2 33 30 34 29 25 
Women 1 1732 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
 2 1391 0.91 (0.85 - 0.98) 0.92 (0.86 - 0.99) 0.93 (0.86 - 0.99) 0.92 (0.86 - 0.99) 0.93 (0.87 - 1.00) 
 3 1255 0.92 (0.86 - 0.99) 0.93 (0.87 - 1.00) 0.94 (0.87 - 1.01) 0.94 (0.88 - 1.01) 0.95 (0.89 - 1.03) 
 4 1176 0.96 (0.89 - 1.03) 0.97 (0.90 - 1.04) 0.98 (0.91 - 1.06) 0.98 (0.91 - 1.06) 0.99 (0.92 - 1.07) 
 5 1208 1.11 (1.03 - 1.20) 1.11 (1.03 - 1.20) 1.13 (1.05 - 1.22) 1.12 (1.03 - 1.20) 1.11 (1.03 - 1.19) 
  Non-linearity p-value p<0.001 p<0.001 p<0.001 p<0.001 0.003 
 2 31 28 29 26 21 
Fat mass (FM) 
Men 1 1573 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
  2 1542 0.89 (0.83 - 0.95) 0.89 (0.83 - 0.95) 0.90 (0.84 - 0.96) 0.89 (0.83 - 0.96) 0.90 (0.84 - 0.96) 
  3 1727 0.97 (0.91 - 1.04) 0.96 (0.90 - 1.03) 0.97 (0.91 - 1.04) 0.96 (0.90 - 1.03) 0.97 (0.90 - 1.04) 
  4 1870 1.05 (0.98 - 1.12) 1.02 (0.96 - 1.1) 1.02 (0.95 - 1.09) 1.00 (0.94 - 1.07) 1.01 (0.94 - 1.08) 
  5 2370 1.35 (1.27 - 1.44) 1.28 (1.2 - 1.37) 1.27 (1.19 - 1.35) 1.22 (1.14 - 1.31) 1.22 (1.14 - 1.31) 
  Non-linearity p-value p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 
 2 198 145 126 101 98 
Women 1 1126 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
 2 1228 0.97 (0.90 - 1.06) 0.97 (0.89 - 1.05) 0.98 (0.90 - 1.06) 0.98 (0.90 - 1.06) 0.99 (0.91 - 1.07) 
 3 1321 0.95 (0.87 - 1.03) 0.94 (0.86 - 1.01) 0.94 (0.86 - 1.02) 0.93 (0.86 - 1.01) 0.94 (0.87 - 1.02) 
 4 1414 1.02 (0.94 - 1.10) 0.99 (0.92 - 1.08) 0.98 (0.91 - 1.07) 0.98 (0.90 - 1.06) 0.99 (0.92 - 1.08) 
 5 1673 1.27 (1.18 - 1.37) 1.21 (1.12 - 1.31) 1.18 (1.09 - 1.28) 1.16 (1.07 - 1.26) 1.17 (1.08 - 1.26) 
 Non-linearity p-value p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 
 2 82 62 47 41 37 
 
Test for non-linearity across quintiles conducted using LRTs with 4df (p<0.05 indicates significant departure from linearity). Adjusted hazard ratios 
(HR) and 95% confidence intervals (CI) obtained using Cox proportional hazard regression. Age at risk adjusted for by using age during study as the 
underlying timescale for Cox regression. Height adjusted for by inclusion as continuous variable for FM and by regression out of variation due to 
height for ASM.  *Sociodemographic characteristics: Townsend index of deprivation, education. †Lifestyle factors: smoking status, alcohol intake, 
physical activity, oily fish intake, fruit and vegetable intake, saturated fat intake. ‡Medical history: diabetes, cancer history, menopause (women). 2 











Table S9. CVD sensitivity analyses. 
 
Hazard ratios of CVD associated with appendicular skeletal muscle mass (aSMM) and fat mass 
(FM)  
 
Test for non-linearity across quintiles conducted using LRTs with 4df (p<0.05 indicates significant departure from linearity). Adjusted hazard ratios 
(HR) and 95% confidence intervals (CI) obtained using Cox proportional hazard regression. Adjusted for age at risk, Townsend index of deprivation, 
education, smoking status, alcohol intake, physical activity, oily fish intake, fruit and vegetable intake, saturated fat intake, diabetes, cancer history, 
menopause (women), and mutually adjusted for FM and ASM. Height is adjusted for by inclusion as continuous variable for FM and by regression 





Remove first 2 years of 
follow up 
Remove outliers 
Remove participants with 
BMI > 35 
No. 
events 
HR (95% CI) 
No.    
events 
HR (95% CI) 
No. 
events 
HR (95% CI) 
Appendicular skeletal muscle mass (aSMM) 
Men 1 3804 1 (reference) 4316 1 (reference) 4283 1 (reference) 
  2 3250 1.06 (1.01 - 1.11) 3715 1.02 (0.97 - 1.06) 3614 1.03 (0.98 - 1.08) 
  3 2939 1.12 (1.06 - 1.17) 3385 1.07 (1.02 - 1.12) 3198 1.07 (1.02 - 1.12) 
  4 2666 1.19 (1.13 - 1.25) 3055 1.1 0(1.05 - 1.16) 2800 1.11 (1.06 - 1.17) 
  5 2597 1.37 (1.30 - 1.44) 2819 1.23 (1.17 - 1.29) 2448 1.25 (1.18 - 1.31) 
Non-linearity p-value  0.038  0.057  0.046 
Women 1 2327 1 (reference) 2582 1 (reference) 2505 1 (reference) 
 2 1947 0.97 (0.91 - 1.03) 2182 0.95 (0.90 - 1.01) 2075 0.96 (0.90 - 1.01) 
 3 1667 0.93 (0.87 - 0.99) 1848 0.89 (0.84 - 0.95) 1699 0.88 (0.83 - 0.94) 
 4 1570 0.96 (0.90 - 1.02) 1753 0.92 (0.87 - 0.98) 1555 0.92 (0.86 - 0.98) 
 5 1681 1.08 (1.01 - 1.15) 1682 1.01 (0.95 - 1.07) 1375 1.01 (0.94 - 1.08) 
Non-linearity p-value  p<0.001  p<0.001  p<0.001 
Fat Mass (FM) 
Men 1 2293 1 (reference) 2565 1 (reference) 2565 1 (reference) 
  2 2701 1.13 (1.07 - 1.19) 3097 1.16 (1.1 - 1.22) 3097 1.16 (1.10 - 1.22) 
  3 2907 1.20 (1.14 - 1.27) 3393 1.26 (1.19 - 1.32) 3393 1.26 (1.19 - 1.32) 
  4 3341 1.36 (1.28 - 1.43) 3835 1.40 (1.33 - 1.47) 3828 1.40 (1.33 - 1.47) 
  5 4014 1.60 (1.51 - 1.68) 3994 1.62 (1.54 - 1.71) 3460 1.61 (1.53 - 1.70) 
Non-linearity p-value  0.038  0.211  0.286 
Women 1 1173 1 (reference) 1313 1 (reference) 1313 1 (reference) 
 2 1487 1.16 (1.07 - 1.25) 1653 1.16 (1.08 - 1.25) 1652 1.15 (1.07 - 1.24) 
 3 1806 1.27 (1.18 - 1.37) 2037 1.30 (1.21 - 1.40) 2037 1.29 (1.21 - 1.39) 
 4 2118 1.48 (1.37 - 1.59) 2357 1.50 (1.40 - 1.60) 2351 1.49 (1.39 - 1.59) 
 5 2608 1.84 (1.71 - 1.98) 2493 1.82 (1.70 - 1.96) 1856 1.76 (1.63 - 1.89) 









Table S10. CVD mediation analyses. 
 



















































Adjusted hazard ratios (HR) and 95% confidence intervals (CI) obtained using Cox proportional hazard regression. Adjusted for age at risk, Townsend 
index of deprivation, education, smoking status, alcohol intake, physical activity, oily fish intake, fruit and vegetable intake, saturated fat intake, 
diabetes, cancer history, menopause (women), and mutually adjusted for FM and ASM ASM (except for the model adjusted for BMI). Height is 
adjusted for by inclusion as continuous variable for FM and by regression out of variation due to height for ASM. Test for non-linearity across 
quintiles conducted using LRTs with 4df (p<0.05 indicates significant departure from linearity). The 2 values were calculated from likelihood 










Appendicular skeletal muscle mass (aSMM) 
Men 1 2861 1 (reference) 1 (reference) 1 (reference) 
  2 2457 0.96 (0.92 - 1.01) 1.02 (0.98 - 1.07) 1.03 (0.99 - 1.08) 
  3 2209 0.97 (0.93 - 1.02) 1.06 (1.02 - 1.11) 1.08 (1.03 - 1.14) 
  4 2004 0.98 (0.93 - 1.03) 1.10 (1.05 - 1.16) 1.14 (1.09 - 1.20) 
  5 1907 1.04 (0.99 - 1.10) 1.23 (1.17 - 1.29) 1.28 (1.21 - 1.35) 
  Non-linearity p-value 0.015 0.031 0.123 
 Main model 2 106 87 74 
 Adjusted model 2 12 79 92 
 % Change  87% 9% 20% 
Women 1 2617 1 (reference) 1 (reference) 1 (reference) 
 2 2182 0.92 (0.87 - 0.97) 0.95 (0.90 - 1.01) 0.93 (0.88 - 0.99) 
 3 1848 0.84 (0.79 - 0.89) 0.90 (0.84 - 0.95) 0.87 (0.82 - 0.93) 
 4 1753 0.84 (0.79 - 0.90) 0.92 (0.87 - 0.98) 0.94 (0.88 - 1.00) 
 5 1885 0.90 (0.85 - 0.96) 1.02 (0.96 - 1.09) 1.04 (0.98 - 1.11) 
  Non-linearity p-value p<0.001 p<0.001 p<0.001 
 Main model 2 51 26 29 
 Adjusted model 2 43 23 30 
 % Change  17% 12% 3% 
Fat mass (FM) 
Men 1 2565 1 (reference) 1 (reference) 1 (reference) 
  2 3097 1.05 (0.99 - 1.10) 1.12 (1.06 - 1.18) 1.09 (1.03 - 1.15) 
  3 3393 1.06 (1.00 - 1.12) 1.19 (1.13 - 1.25) 1.15 (1.09 - 1.22) 
  4 3835 1.09 (1.03 - 1.16) 1.29 (1.22 - 1.36) 1.27 (1.20 - 1.34) 
  5 4609 1.10 (1.01 - 1.19) 1.48 (1.41 - 1.56) 1.49 (1.41 - 1.58) 
  Non-linearity p-value 0.726 0.102 0.009 
 Main model 2 455 453 398 
 Adjusted model 2 8 274 252 
 % Change  98% 40% 37% 
Women 1 1313 1 (reference) 1 (reference) 1 (reference) 
 2 1653 1.07 (0.99 - 1.16) 1.12 (1.05 - 1.21) 1.13 (1.05 - 1.23) 
 3 2037 1.13 (1.05 - 1.22) 1.23 (1.15 - 1.32) 1.25 (1.16 - 1.35) 
 4 2357 1.21 (1.11 - 1.32) 1.37 (1.28 - 1.47) 1.40 (1.30 - 1.52) 
 5 2925 1.29 (1.15 - 1.46) 1.64 (1.54 - 1.76) 1.73 (1.60 - 1.87) 
 Non-linearity p-value 0.991 0.119 0.047 
 Main model 2 430 429 398 
 Adjusted model 2 20 258 259 









Table S11. Mortality sensitivity analyses. 
 
Hazard ratios of all-cause mortality associated with appendicular skeletal muscle mass (aSMM) 
and fat mass (FM)  
 
Adjusted hazard ratios (HR) and 95% confidence intervals (CI) obtained using Cox proportional hazard regression. Adjusted for age at risk, Townsend 
index of deprivation, education, smoking status, alcohol intake, physical activity, oily fish intake, fruit and vegetable intake, saturated fat intake, 
diabetes, cancer history, menopause (women), and mutually adjusted for FM and ASM. Height is adjusted for by inclusion as continuous variable for 
FM and by regression out of variation due to height for ASM. Test for non-linearity across quintiles conducted using LRTs with 4df (p<0.05 indicates 




Remove first 2 years of 
follow up 
Remove outliers 
Remove participants with 
BMI > 35 
No. 
events 
HR (95% CI) 
No.    
events 
HR (95% CI) 
No. 
events 
HR (95% CI) 
Appendicular skeletal muscle mass (aSMM) 
Men 1 2532 1 (reference) 2660 1 (reference) 2648 1 (reference) 
  2 1897 1.00 (0.94 - 1.06) 2013 0.98 (0.92 - 1.04) 1941 0.98 (0.92 - 1.04) 
  3 1566 1.02 (0.96 - 1.09) 1673 0.99 (0.93 - 1.06) 1568 0.98 (0.92 - 1.05) 
  4 1283 1.03 (0.97 - 1.11) 1378 1.00 (0.93 - 1.07) 1259 0.99 (0.93 - 1.06) 
  5 1219 1.22 (1.14 - 1.31) 1263 1.16 (1.08 - 1.24) 1076 1.13 (1.05 - 1.22) 
Non-linearity p-value  0.004  0.002  0.011 
Women 1 1647 1 (reference) 1712 1 (reference) 1663 1 (reference) 
 2 1307 0.93 (0.86 – 1.00) 1391 0.93 (0.87 – 1.00) 1327 0.93 (0.86 - 1.00) 
 3 1183 0.96 (0.89 - 1.03) 1255 0.95 (0.89 - 1.03) 1159 0.93 (0.86 - 1.00) 
 4 1119 1.01 (0.93 - 1.09) 1176 0.99 (0.92 - 1.07) 1072 0.98 (0.90 - 1.05) 
 5 1148 1.13 (1.05 - 1.22) 1093 1.09 (1.01 - 1.18) 932 1.06 (0.98 - 1.15) 
Non-linearity p-value  0.001  0.008  0.006 
Fat Mass (FM) 
Men 1 1468 1 (reference) 1573 1 (reference) 1573 1 (reference) 
  2 1451 0.90 (0.84 - 0.97) 1542 0.90 (0.83 - 0.96) 1542 0.89 (0.83 - 0.96) 
  3 1620 0.97 (0.90 - 1.04) 1727 0.97 (0.90 - 1.04) 1727 0.97 (0.90 - 1.03) 
  4 1742 1.00 (0.93 - 1.07) 1870 1.01 (0.94 - 1.08) 1869 1.00 (0.94 - 1.07) 
  5 2216 1.22 (1.14 - 1.30) 2039 1.19 (1.11 - 1.27) 1781 1.17 (1.09 - 1.25) 
Non-linearity p-value  p<0.001  p<0.001  p<0.001 
Women 1 1058 1 (reference) 1126 1 (reference) 1126 1 (reference) 
 2 1162 0.99 (0.91 - 1.07) 1228 0.98 (0.90 - 1.06) 1228 0.98 (0.90 - 1.06) 
 3 1244 0.94 (0.86 - 1.02) 1321 0.94 (0.87 - 1.02) 1321 0.93 (0.86 - 1.01) 
 4 1336 0.99 (0.91 - 1.07) 1414 0.99 (0.91 - 1.07) 1409 0.98 (0.90 - 1.06) 
 5 1604 1.18 (1.09 - 1.28) 1422 1.12 (1.03 - 1.22) 1069 1.08 (0.99 - 1.17) 
Non-linearity p-value  p<0.001  0.001  0.018 









Table S12. Mortality mediation analyses. 
 
Hazard ratios of all-cause mortality associated with appendicular skeletal muscle mass (aSMM) 




















































Adjusted hazard ratios (HR) and 95% confidence intervals (CI) obtained using Cox proportional hazard regression. Adjusted for age at risk, Townsend 
index of deprivation, education, smoking status, alcohol intake, physical activity, oily fish intake, fruit and vegetable intake, saturated fat intake, 
diabetes, cancer history, menopause (women), and mutually adjusted for FM and ASM (except for the model adjusted for BMI). Height is adjusted 
for by inclusion as continuous variable for FM and by regression out of variation due to height for ASM. Test for non-linearity across quintiles 
conducted using LRTs with 4df (p<0.05 indicates significant departure from linearity). The 2 values were calculated from likelihood ratio tests 





Adjust for BMI 
Adjust for 
hypertension 
Adjust for  
cholesterol 
Appendicular skeletal muscle mass (aSMM) 
Men 1 2706 1 (reference) 1 (reference) 1 (reference) 
  2 2013 0.95 (0.89 - 1.01) 0.98 (0.92 - 1.04) 0.98 (0.92 - 1.05) 
  3 1673 0.95 (0.89 - 1.01) 0.99 (0.93 - 1.05) 0.97 (0.91 - 1.04) 
  4 1378 0.93 (0.87 - 1.00) 0.99 (0.93 - 1.06) 0.96 (0.89 - 1.03) 
  5 1312 1.06 (0.98 - 1.14) 1.15 (1.07 - 1.23) 1.13 (1.05 - 1.22) 
  Non-linearity p-value 0.001 0.002 0.001 
 Main model 2 29 25 21 
 Adjusted model 2 16 24 20 
 % Change  45% 4% 5% 
Women 1 1732 1 (reference) 1 (reference) 1 (reference) 
 2 1391 0.92 (0.86 - 0.99) 0.93 (0.87 - 1.00) 0.93 (0.86 - 1.00) 
 3 1255 0.93 (0.87 - 1.00) 0.95 (0.89 - 1.03) 0.95 (0.88 - 1.03) 
 4 1176 0.96 (0.89 - 1.03) 0.99 (0.92 - 1.07) 0.99 (0.91 - 1.07) 
 5 1208 1.06 (0.98 - 1.14) 1.10 (1.02 - 1.19) 1.10 (1.02 - 1.20) 
  Non-linearity p-value 0.003 0.003 0.004 
 Main model 2 26 21 21 
 Adjusted model 2 16 20 19 
 % Change  38% 5% 9% 
Fat mass (FM) 
Men 1 1573 1 (reference) 1 (reference) 1 (reference) 
  2 1542 0.86 (0.79 - 0.92) 0.88 (0.82 - 0.95) 0.90 (0.84 - 0.97) 
  3 1727 0.90 (0.83 - 0.97) 0.94 (0.88 - 1.01) 0.98 (0.91 - 1.06) 
  4 1870 0.90 (0.82 - 0.98) 0.97 (0.91 - 1.04) 1.01 (0.94 - 1.09) 
  5 2370 1.01 (0.90 - 1.13) 1.17 (1.09 - 1.25) 1.24 (1.15 - 1.34) 
  Non-linearity p-value p<0.001 p<0.001 p<0.001 
 Main model 2 101 98 88 
 Adjusted model 2 36 81 87 
 % Change  64% 17% 1% 
Women 1 1126 1 (reference) 1 (reference) 1 (reference) 
 2 1228 0.91 (0.84 - 0.99) 0.98 (0.90 - 1.06) 0.97 (0.89 - 1.06) 
 3 1321 0.82 (0.75 - 0.90) 0.93 (0.86 - 1.01) 0.97 (0.89 - 1.06) 
 4 1414 0.81 (0.73 - 0.90) 0.97 (0.90 - 1.06) 1.00 (0.91 - 1.09) 
 5 1673 0.83 (0.71 - 0.96) 1.13 (1.05 - 1.23) 1.16 (1.06 - 1.27) 
 Non-linearity p-value 0.033 p<0.001 0.003 
 Main model 2 41 37 31 
 Adjusted model 2 22 31 26 









Figure S1. Exclusions and selection of the study population included in the analysis from the 
UK Biobank. 
 
Mixed, Asian, Black, Chinese or other ethnic background  
(n=22,644) 
Following exclusion of 
non-white ethnicity 
(n=363,341) 
UK Biobank participants 
(n = 502,664) 
Following exclusion of 
those with prior disease 
(n =385,985) 
Following exclusion of 
those with missing data on 
key variables 
(n = 356,590) 
Exclusions due to prevalent CVD or medical conditions 
affecting body-composition: 
Prevalent CVD (n = 37,116)* 
Cancer in last 5 years (n = 17,710) 
Type 1 diabetes (n = 3,952) 
More than 1 fall in last year (n = 26,623) 
Respiratory diseases (n = 8,845)† 
Renal failure (n = 260) 
Endocrine disease (n = 3,050)‡ 
Musculoskeletal disorder (9,324)§ 
HIV, cirrhosis or other diseases (n = 755)‖  
Self-reported poor health (n = 8,558) 
Pregnancy (n = 327) 
 
Excluded participants with missing or unknown data on 
aSMM, FM, height, grip strength, waist circumference   
(n = 6,751) 
*Prior CVD: follows the same definition and codes from HES reported in the manuscript as well as self-reported from 
verbal interviews and touchscreen questionnaire including instances of heart attack/myocardial infarction, heart 
failure, angina, heart failure, stroke, transient ischaemic attack, subdural haemorrhage, aortic aneurysm rupture, 
cerebral aneurysm, peripheral vascular disease, leg claudication, arterial embolism, . 
†Respiratory diseases: chronic obstructive pulmonary disease, emphysema, chronic bronchitis, bronchiectasis 
(occurred anytime) 
‡Endocrine diseases: Cushing’s syndrome, hyperthyroidism (occurred anytime) 
§Musculoskeletal diseases: motor neurone disease, osteoporosis, rheumatoid arthritis, fractures (occurred anytime) 
‖HIV, cirrhosis or other disease: pancreatitis, encephalitis, meningitis, intracranial abscess, empyema, Stevens Johnson 









Figure S2. Splines. 
 
Adjusted hazard ratios (HRs) of incident cardiovascular disease (CVD) and all-cause mortality 
associated with appendicular skeletal muscle mass (aSMM), whole body fat mass (FM) and body 
















Figure S3. Associations with CVD subtypes. 
 
Adjusted hazard ratios for the association between cardiovascular disease (CVD) subtypes 
(coronary heart disease, stroke and congestive heart failure) with i) appendicular skeletal 
muscle mass (aSMM) and ii) fat mass (FM) 




i A, adjusted hazard ratios for the association between CVD subtypes with aSSM in men. i B, adjusted hazard ratios for the association 
between CVD subtypes with aSSM in women. ii A, adjusted hazard ratios for the association between CVD subtypes with FM in men. 
ii B, adjusted hazard ratios for the association between CVD subtypes with FM in women 
Adjusted hazard ratios (HR) and 95% group-specific confidence intervals (CI) obtained using floated absolute risk method of Cox 
proportional hazard regression. Adjusted for age at risk, Townsend index of deprivation, education, smoking status, alcohol intake, 
physical activity, oily fish intake, fruit and vegetable intake, saturated fat intake, diabetes, cancer history, menopause (women), and 
mutually adjusted for FM and ASM. Height is adjusted for by inclusion as continuous variable for FM and by regression out of 
variation due to height for ASM. HRs are plotted at the mean of the resurvey values for the baseline-defined quintiles (“usual” values) 
to correct for measurement error. 
i) Appendicular skeletal muscle mass 
(aSMM) 
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